77 results on '"Salvadori, N."'
Search Results
2. HIV-Dementia Scale as a screening tool for the detection of subcortical cognitive deficits: validation of the Italian version
- Author
-
Montanucci, C., Chipi, E., Salvadori, N., Rinaldi, R., Eusebi, P., and Parnetti, L.
- Published
- 2021
- Full Text
- View/download PDF
3. Tenofovir Versus Placebo to Prevent Perinatal Transmission of Hepatitis B
- Author
-
Jourdain, G., Ngo-Giang-Huong, N., Harrison, L., Decker, L., Khamduang, W., Tierney, C., Salvadori, N., Cressey, T.R., Sirirungsi, W., Achalapong, J., Yuthavisuthi, P., Kanjanavikai, P., Ayudhaya, O.P. Na, Siriwachirachai, T., Prommas, S., Sabsanong, P., Limtrakul, A., Varadisai, S., Putiyanun, C., Suriyachai, P., Liampongsabuddhi, P., Sangsawang, S., Matanasarawut, W., Buranabanjasatean, S., Puernngooluerm, P., Bowonwatanuwong, C., Puthanakit, T., Klinbuayaem, V., Thongsawat, S., Thanprasertsuk, S., Siberry, G.K., Watts, D.H., Chakhtoura, N., Murphy, T.V., Nelson, N.P., Chung, R.T., Pol, S., and Chotivanich, N.
- Published
- 2018
- Full Text
- View/download PDF
4. VON NEUMANN, THE CLASSICAL ECONOMISTS AND ARROW–DEBREU : SOME NOTES
- Author
-
KURZ, H. D. and SALVADORI, N.
- Published
- 2004
5. Cross-sectional clinical, neuropsychological, neuroimaging, and neurophysiological characterization of mild cognitive impairment patients in WP5 PharmaCog/E-ADNI study: EP1105
- Author
-
Galluzzi, S., Marizzoni, M., Babiloni, C., Bartres-Faz, D., Blin, O., Bordet, R., Bosch, B., De Anna, F., Didic, M., Farotti, L., Forloni, G., Jovicich, J., Marra, C., Marzano, N., Molinuevo, J. L., Nobili, F., Pariente, J., Parnetti, L., Payoux, P., Picco, A., Quaranta, D., Ranjeva, J.-P., Roccatagliata, L., Rossini, P. M., Salvadori, N., Schonknecht, P., Soricelli, A., Tsolaki, M., Vecchio, F., Visser, P. J., Wiltfang, J., and Frisoni, G. B.
- Published
- 2014
6. Time trends, frequency, characteristics and prognosis of short‐duration transient global amnesia.
- Author
-
Romoli, M., Tuna, M. A., Li, L., Paciaroni, M., Giannandrea, D., Tordo Caprioli, F., Lotti, A., Eusebi, P., Mosconi, M. G., Pellizzaro Venti, M., Salvadori, N., Gili, A., Ricci, S., Stracci, F., Sarchielli, P., Parnetti, L., Rothwell, P. M., and Calabresi, P.
- Subjects
AMNESIA ,CARDIOVASCULAR diseases ,PROGNOSIS ,SEIZURES (Medicine) ,EPILEPSY - Abstract
Background and purpose: Transient global amnesia (TGA) is characterized by a sudden onset of anterograde amnesia lasting up to 24 h. One major differential for TGA is transient epileptic amnesia, which typically lasts < 1 h. However, TGA can also be short in duration and little is known about the time trends, characteristics and prognosis of TGA cases lasting < 1 h. Methods: We compared the clinical features of TGA ascertained in two independent cohort studies in Oxfordshire, UK [Oxford cohort 1977–1987 versus Oxford Vascular Study (OXVASC) 2002–2018] to determine the time trends of clinical features of TGA. Results were validated in another independent contemporary TGA cohort in Italy [Northern Umbria TGA registry (NU) 2002–2018]. We compared the risk factors, clinical features and long‐term prognosis (major cardiovascular events, recurrent TGA and seizure/epilepsy) of patients presenting with episodes lasting < 1 h versus those lasting ≥ 1 h. Results: Overall, 639 patients with TGA were included (114 Oxford cohort, 100 OXVASC, 425 NU). Compared with the original Oxford cohort, there were more cases with TGA lasting < 1 h in OXVASC [32 (32.0%) vs. 9 (8.8%)] and NU (11.8% vs. 8.8% in Oxford cohort). In both OXVASC and NU, patient age, vascular risk factors and clinical features were largely similar between those with TGA lasting < 1 h versus those lasting ≥ 1 h. Moreover, there was no difference in the long‐term risk of seizure/epilepsy or major cardiovascular events between TGA lasting < 1 h versus TGA lasting ≥ 1 h. Conclusions: Short‐duration TGA episodes (<1 h) were not uncommon and were more frequent than in earlier studies. The clinical features and long‐term prognosis of short‐duration TGA did not differ from more typical episodes lasting ≥ 1 h. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. LBP-032 - Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in noncirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: The STORM-C-1 phase II/III trial
- Author
-
Andrieux-Meyer, I., Tan, S.-S., Salvadori, N., Simon, F., Cressey, T.R., Said, H.R.H.M., Hassan, M.R.A., Omar, H., Tee, H.P., Chan, W.-K., Goh, K.L., Omar, S.F.S., Kamarulzaman, A., Kumar, S., Thongsawat, S., Thetket, K., Avihingsanon, A., Khemnark, S., Thanprasertsuk, S., Piedagne, J.-M., Brenner, J., Siva, S., Asimah, N., Da Silva, N., Pecoul, B., Lallemant, M., and Murad, S.
- Published
- 2018
- Full Text
- View/download PDF
8. THE RATE OF PROFIT IN AN EXPANDING ECONOMY: SOME EXISTENCE, UNIQUENESS AND STABILITY CONDITIONS.
- Author
-
Marrelli, M. and Salvadori, N.
- Subjects
PROFIT ,ECONOMIC development ,ECONOMIC equilibrium - Abstract
In this paper we intend to (a) show that the restriction Pasinetti imposes on the set of techniques s[sub w] < gx < s[sub c] (1) where s[sub c] and s[sub w] are the capitalists' and workers' saving ratios and g is the exogenously given growth rate, is not sufficient to ensure the existence of an equilibrium growth path, if we take into account the general case which allows for the possibility of joint production (section II); (b) take up the case where the interest rate differs from the capitalists' profit rate: in this case the Pasinetti distribution will be undetermined unless we have a theory of the rate of interest; Pasinetti assumes this last variable to be determined somewhere else in the system and makes it equal to a given proportion of the capitalists' profit rate. We will examine what features a theory of the rate of interest should have in order to close the model (section IV) and what assumptions we need to make about the "set of techniques" in order to ensure the uniqueness of the Pasinetti distribution (section III); (c) study the stability aspects of the Pasinetti process. This type of analysis has already been carried out by Pasinetti himself for the case of a constant capital/output ratio [4, pp. 275-277] and by Samuelson and Modigliani for the case of a neoclassical production function [11, pp. 281.282], but we do not know of any analysis for the general case. Finally, since throughout our paper we consider the case of a flexible capital/output ratio, while Pasinetti seems to believe that the "most reasonable assumption to make on K/Y is, after all, Harrod-Domar's original assumption that K/Y will remain constant" [8, p. 134] when the rate of profit changes, we study under which conditions this is true in the appendix following the paper. [ABSTRACT FROM AUTHOR]
- Published
- 1979
- Full Text
- View/download PDF
9. ON A NEW VARIETY OF RENT.
- Author
-
Salvadori, N.
- Published
- 1983
- Full Text
- View/download PDF
10. Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment.
- Author
-
Panjasawatwong N, Avihingsanon A, Menétrey C, Ribeiro I, Salvadori N, Swanson A, Gillon J-Y, Tan S-S, Thanprasertsuk S, Thongsawat S, and Cressey TR
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Sofosbuvir pharmacokinetics, Sofosbuvir therapeutic use, Cyclopropanes, Hepacivirus drug effects, Hepacivirus genetics, Alkynes, Thailand, Benzoxazines pharmacokinetics, Benzoxazines therapeutic use, Liver Cirrhosis drug therapy, Drug Therapy, Combination, Benzimidazoles, Hepatitis C, Chronic drug therapy, Antiviral Agents pharmacokinetics, Antiviral Agents therapeutic use, HIV Infections drug therapy, HIV Infections virology, Valine pharmacokinetics, Valine analogs & derivatives
- Abstract
Ravidasvir (RDV) is a novel NS5A inhibitor that exhibits potent pan-genotypic inhibition of hepatitis C virus (HCV) replication. Sofosbuvir (SOF) plus RDV was demonstrated to be efficacious and safe in adults with active HCV infection, including those living with HIV (LWHIV), in the STORM-C-1 trial. We assessed the population pharmacokinetics (PK) of RDV in a sub-study nested within STORM-C-1 conducted in Thailand and Malaysia. SOF (400 mg) plus RDV (200 mg) was administered orally once daily for 12 weeks to adults with chronic HCV infection, but without cirrhosis and for 24 weeks to those with compensated cirrhosis. Intensive and sparse PK samples were collected at 4, 8, and 12 weeks after treatment initiation. Population PK parameters of RDV and the impact of covariates were evaluated using nonlinear mixed-effects modeling. Five hundred ninety-four participants were included, 235 (40%) had compensated cirrhosis, and 189 (32%) were LWHIV. RDV plasma concentrations were best described by a two-compartment model with first-order elimination. Oral clearance (CL/F) and volume of distribution (Vd/F) parameters were allometrically scaled on fat-free mass. Concomitant antiretroviral treatment (ART) increased RDV CL/F by 30%-60%, with efavirenz-based ART having the largest impact. Females had 16% lower RDV CL/F than males, and higher albumin levels reduced RDV central volume of distribution. While several covariates impact RDV CL/F and Vd/F, the effect on RDV exposures was not clinically relevant based on the efficacy data reported in this diverse Asian adult population. There were no meaningful drug-drug interactions in adults LWHIV on ART., Competing Interests: C.M., I.R., A.S., and J.-Y.G. are employed by the DNDi. All other authors declare no competing interests.
- Published
- 2024
- Full Text
- View/download PDF
11. Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand.
- Author
-
Salvadori N, Jourdain G, Krittayaphong R, Siripongboonsitti T, Kongsaengdao S, Atipornwanich K, Sakulkonkij P, Angkasekwinai N, Sirijatuphat R, Chusri S, Mekavuthikul T, Apisarnthanarak A, Srichatrapimuk S, Sungkanuparph S, Kirdlarp S, Phongnarudech T, Sangsawang S, Napinkul P, Achalapong J, Khusuwan S, Pratipanawat P, Nookeu P, Danpipat N, Leethong P, Hanvoravongchai P, Sukrakanchana PO, and Auewarakul P
- Subjects
- Humans, Male, Female, Thailand, Middle Aged, Adult, Cytidine therapeutic use, Cytidine adverse effects, Cytidine administration & dosage, Hydroxylamines therapeutic use, Hydroxylamines adverse effects, Hydroxylamines administration & dosage, Aged, Treatment Outcome, COVID-19, Outpatients, Amides therapeutic use, Pyrazines therapeutic use, Pyrazines adverse effects, Pyrazines administration & dosage, COVID-19 Drug Treatment, Antiviral Agents therapeutic use, Antiviral Agents adverse effects, Antiviral Agents administration & dosage, SARS-CoV-2, Cytidine analogs & derivatives
- Abstract
Objectives: Evaluate and compare the efficacy and safety of molnupiravir and favipiravir in outpatients with mild to moderate COVID-19 and at risk of severe COVID-19., Methods: In an open-label, parallel-group, multicenter trial in Thailand, participants with moderate COVID-19 and at least one factor associated with severe COVID-19 were randomly assigned 1:1 to receive oral molnupiravir or oral favipiravir (standard of care). Phone calls for remote symptom assessment were made on Days 6, 15, and 29. Participants with worsening symptoms were instructed to return to the hospital. The primary endpoint was pulmonary involvement by Day 29, as evidenced by ≥2 of the following: dyspnea, oxygen saturation <92% or imaging., Results: Nine hundred seventy-seven participants (487 molnupiravir, 490 favipiravir) were enrolled from 8 July 2022 to 19 January 2023. 98% had received ≥1 dose of COVID-19 vaccine and 83% ≥3 doses. By Day 29, pulmonary involvement occurred in 0% (0/483) in molnupiravir arm versus 1% (5/482) in favipiravir arm (-1.0%; Newcombe 95.2% CI: -2.4% to -0.0%; P = 0.021); all-cause death in 0% (0/483) and <1% (1/482); COVID-19 related hospitalization in <1% (1/483) and 1% (3/482); treatment-related adverse event in 1% (5/483) and 1% (4/486); and serious adverse event in 1% (4/483) and 1% (4/486)., Conclusions: Favipiravir and molnupiravir had a similar efficacy and safety profile. Whether either of the two reduced the risk of complications during the omicron era in this population with a low risk of pulmonary involvement and a high vaccine coverage remains unclear. There were no differences in any of the safety endpoints., Thai Clinical Trials Registry Id: TCTR20230111009., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Predictive value for cerebrospinal fluid Alzheimer's disease profile of different measures of verbal episodic memory in patients with MCI.
- Author
-
Salvadori N, Torrigiani EG, Paoletti FP, Chipi E, Montanucci C, Verderosa C, Siena E, Fruttini D, and Parnetti L
- Subjects
- Humans, Male, Female, Aged, Retrospective Studies, Middle Aged, ROC Curve, Verbal Learning physiology, Predictive Value of Tests, Aged, 80 and over, Alzheimer Disease cerebrospinal fluid, Alzheimer Disease diagnosis, Memory, Episodic, Cognitive Dysfunction cerebrospinal fluid, Cognitive Dysfunction diagnosis, Biomarkers cerebrospinal fluid, Neuropsychological Tests
- Abstract
Neuropsychological evidence of memory impairment represents the main feature of the clinical onset of typical Alzheimer's disease (AD). Rey's Auditory Verbal Learning Test (RAVLT) and Logical Memory (LM) are two tests both assessing verbal episodic memory, widely used in clinical practice. Our aim was to investigate the added value of their combined use in predicting cerebrospinal fluid (CSF) AD biomarkers positivity in a retrospective consecutive series of patients with mild cognitive impairment (MCI). 169 MCI patients were included. For all of them neuropsychological assessment and CSF analysis were available. According to CSF A/T/(N) profile, 109 were defined as MCI due to AD (A+T+), and 60 were non-AD MCI (A-T-). Logistic regression model and receiver-operating characteristic (ROC) curves were analyzed to evaluate the discriminatory power of single and combined sub-measures between AD and non-AD patients. The combination of RAVLT-del with LM could acceptably discriminate the two groups (AUC: 0.69, CI 95% 0.617-0.761, sens: 0.75, spec. 0.58, p < 0.001), while the single tests did not show sufficient discriminative performance. Our study shows that the combination of RAVLT delayed recall with LM better predicts the biological AD diagnosis (A+T+), showing a good discriminative power between MCI-AD from non-AD MCI. Since RAVLT and LM assess different components of verbal episodic memory, they should be considered as complementary, rather than interchangeable, tests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
13. Real-world evidence of survival benefit of remdesivir: study of 419 propensity score-matched patients hospitalized over the alpha and delta waves of COVID-19 in New Orleans, LA.
- Author
-
Salvadori N, Fridman M, Chiang M, Chen L, Wang C, Lee E, Fonseca V, Fusco DN, Jourdain G, and Drouin AC
- Abstract
Background: The direct acting antiviral remdesivir (RDV) has shown promising results in randomized clinical trials. This study is a unique report of real clinical practice RDV administration for COVID-19 from alpha through delta variant circulation in New Orleans, Louisiana (NOLA). Patients in NOLA have among US worst pre-COVID health outcomes, and the region was an early epicenter for severe COVID., Methods: Data were directly extracted from electronic medical records through REACHnet. Of 9,106 adults with COVID, 1,928 were admitted to inpatient care within 7 days of diagnosis. The propensity score is based upon 22 selected covariates, related to both RDV assignment and outcome of interest. RDV and non-RDV patients were matched 1:1 with replacement, by location and calendar period of admission. Primary and secondary endpoints were, death from any cause and inpatient discharge, within 28 and 14 days after inpatient admission., Results: Of 448 patients treated with RDV, 419 (94%) were successfully matched to a non-RDV patient. 145 (35%) patients received RDV for < 5 days, 235 (56%) for 5 days, and 39 (9%) for > 5 days. 96% of those on RDV received it within 2 days of admission. RDV was more frequently prescribed in patients with pneumonia (standardized difference: 0.75), respiratory failure, hypoxemia, or dependence on supplemental oxygen (0.69), and obesity (0.35) within 5 days prior to RDV initiation or corresponding day in non-RDV patients (index day). RDV patients were numerically more likely to be on steroids within 5 days prior to index day (86 vs. 82%) and within 7 days after inpatient admission (96 vs. 87%). RDV was significantly associated with lower risk of death within 14 days after admission (hazard ratio [HR]: 0.37, 95% CI: 0.19 to 0.69, p = 0.002) but not within 28 days (HR: 0.62, 95% CI: 0.36 to 1.07, p = 0.08). Discharge within 14 days of admission was significantly more likely for RDV patients ( p < 0.001) and numerically more likely within 28 days after admission ( p = 0.06)., Conclusion: Overall, our findings support recommendation of RDV administration for COVID-19 in a highly comorbid, highly impoverished population representative of both Black and White subjects in the US Gulf South., Competing Interests: The study team reports receiving investigator-initiated research support from: Gilead Sciences, Inc. (AD, DF, NS, GJ, MF), a contract from the Center for Diseases Control (AD, DF), a National Institute of Health SEROnet study (AD, DF), and clinical trials support from Gilead (AD, DF), Regeneron (AD, DF), Metro International Biotech (AD, DF), and NIH-DMID COVAIL (AD, DF). DF also reports consultant fees from and has served an advisory boards for Gilead Sciences, Inc., unrelated to this work. MF was employed by AMF Consulting. MC, LC, CW, EL were employed by Gilead Sciences, Inc. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Salvadori, Fridman, Chiang, Chen, Wang, Lee, Fonseca, Fusco, Jourdain and Drouin.)
- Published
- 2024
- Full Text
- View/download PDF
14. Intrathecal B cell activation and memory impairment in multiple sclerosis.
- Author
-
Gaetani L, Salvadori N, Brachelente G, Sperandei S, Di Sabatino E, Fiacca A, Mancini A, Villa A, De Stefano N, Parnetti L, and Di Filippo M
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Adult, Magnetic Resonance Imaging, Cognitive Dysfunction etiology, Cognitive Dysfunction physiopathology, Brain diagnostic imaging, Brain pathology, Lymphocyte Activation, Neuropsychological Tests, B-Lymphocytes immunology, Memory Disorders etiology, Memory Disorders diagnostic imaging, Multiple Sclerosis immunology, Multiple Sclerosis complications, Multiple Sclerosis diagnostic imaging
- Abstract
Background: Cognitive impairment (CI) is a common and disabling feature of people with multiple sclerosis (pwMS), but its underlying mechanisms are heterogenous and not fully understood. A role of infiltrating immune cells in the meninges and brain parenchyma has been hypothesized. This study aimed to explore the hypothesis that intrathecal B cells might influence cognitive performance in pwMS., Methods: A retrospective study was performed on 39 newly diagnosed pwMS who underwent cerebrospinal fluid (CSF) analysis. Kappa (κ)-index was measured as a biomarker of intrathecal B cell activation. Cognitive performance was assessed using the Brief Repeatable Battery of Neuropsychological Tests (BRBN). Brain T2 lesions number (T2LN) and volume (T2LV) together with brain, cortical grey matter, thalamic and hippocampal volumes were calculated to account for MRI-visible damage., Results: κ-index was higher in pwMS with verbal memory impairment (median 99.6, range 58.5-195.2 vs. median 37.2, range 2.3-396.9, p < 0.001), and it was negatively associated with BRBN tests exploring verbal memory and information processing speed. In multivariate models, higher κ-index was confirmed to be independently associated with worse scores of BRBN tests exploring verbal memory and with a higher probability of verbal memory impairment., Conclusion: Intrathecal B cells might drive memory impairment in pwMS independently of brain damage visible on MRI scans., Competing Interests: Declaration of competing interest LG participated on advisory boards for, and received writing honoraria and travel grants from Almirall, Biogen, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers and Teva. AM participated on advisory boards for, and received writing honoraria and travel grants to attend national and international conferences from Alexion, Almirall, Biogen Idec, Merck, Mylan, Novartis, Sanofi and Teva. NDS participated on advisory boards for and received speaker or writing honoraria and funding for travelling from Bayer, Biogen Idec, Bristol, Genzyme, Immunic, Merck, Novartis, Roche, and Teva. MDF participated on advisory boards and steering committees for and received speaker or writing honoraria, research support and funding for travelling from Alexion, BMS, Bayer, Biogen Idec, Genzyme, Horizon, Janssen, Merck, Mylan, Novartis, Roche, Siemens Healthineers, Teva and Viatris. NS, GB, SS, AF, EDS, AV, and LP report no conflict of interest., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
15. Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay.
- Author
-
Bellomo G, Toja A, Paolini Paoletti F, Ma Y, Farris CM, Gaetani L, Salvadori N, Chiasserini D, Wojdaƚa AL, Concha-Marambio L, and Parnetti L
- Subjects
- Humans, alpha-Synuclein cerebrospinal fluid, Biomarkers cerebrospinal fluid, tau Proteins cerebrospinal fluid, Amyloid beta-Peptides cerebrospinal fluid, Alzheimer Disease cerebrospinal fluid, Synucleinopathies, Lewy Body Disease cerebrospinal fluid, Parkinson Disease cerebrospinal fluid
- Abstract
Introduction: Lewy body disease, a frequently observed co-pathology in Alzheimer's disease (AD), can be identified antemortem in cerebrospinal fluid (CSF) by α-synuclein seed amplification assay (αS-SAA). The prevalence and clinical impact of CSF αS-SAA positivity in AD are still unknown., Methods: αS-SAA was performed on CSF samples from 240 AD patients (preclinical, prodromal, and dementia stages), 85 controls, 84 patients with Parkinson's disease (PD), and 21 patients with PD with dementia or dementia with Lewy bodies. In AD patients, associations between αS-SAA positivity and cognitive changes were also evaluated., Results: In agreement with available neuropathological studies, αS-SAA positivity was observed in 30% of AD patients (vs 9% in controls), and was associated with cognitive decline, visuospatial impairment, and behavioral disturbances., Discussion: αS-SAA positivity in AD patients reflects the prevalence observed in neuropathological series and is associated with a worse clinical outcome. These data confirm the validity of CSF αS-SAA positivity as biomarker of synucleinopathy., (© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
- Published
- 2024
- Full Text
- View/download PDF
16. Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial.
- Author
-
Bekker A, Salvadori N, Rabie H, du Toit S, Than-In-At K, Groenewald M, Cressey R, Nielsen J, Capparelli EV, Lallemant M, Cotton MF, and Cressey TR
- Subjects
- Infant, Infant, Newborn, Humans, Child, Lamivudine, Ritonavir, Lopinavir therapeutic use, South Africa, Dideoxynucleosides adverse effects, Drug Therapy, Combination, Anti-Retroviral Agents therapeutic use, Tablets, HIV Infections drug therapy, HIV-1, Anti-HIV Agents therapeutic use, Cyclopropanes, Dideoxyadenosine analogs & derivatives
- Abstract
Background: Existing solid antiretroviral fixed-dose combination formulations are preferred over liquid formulations in children, but their suitability for neonates is unknown. We evaluated the pharmacokinetics and safety of paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates., Methods: In this open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial, generic abacavir- lamivudine (120:60 mg) double-scored dispersible tablets and lopinavir boosted with ritonavir (40:10 mg) granules were studied. Neonates exposed to HIV (≥37 weeks gestational age) of no more than 3 days of age with birthweights of 2000-4000 g were identified through routine care in a tertiary hospital in Cape Town, South Africa. In stage 1, the pharmacokinetics and safety of two single doses were assessed to select the multidose strategy for stage 2. Neonates received a single dose of abacavir-lamivudine (30:15 mg, a quarter of a tablet) and lopinavir boosted with ritonavir (40:10 mg - one sachet) orally between 3 days and 14 days of age, and a second dose of a quarter tablet of abacavir-lamivudine and lopinavir boosted with ritonavir (80:20 mg, two sachets) 10-14 days later in stage 1. The multidose strategy selected in stage 2 was a quarter of the abacavir-lamivudine (30:15 mg) fixed-dose dispersible tablet once per day and two sachets of the lopinavir boosted with ritonavir (80:20 mg) granules twice per day from birth to age 28 days. In both stages two intensive pharmacokinetic visits were done, one at less than 14 days of life (pharmacokinetics 1) and another 10-14 days later (pharmacokinetics 2). Safety visits were done 1-2 weeks after each pharmacokinetic visit. Primary objectives were to assess pharmacokinetics and safety of abacavir, lamivudine, and lopinavir. Pharmacokinetic endpoints were area under the concentration time curve (AUC), maximum concentration, and concentration at end of dosing interval in all participants with at least one evaluable pharmacokinetic visit. Safety endpoints included grade 3 or worse adverse events, and grade 3 or worse treatment-related adverse events, occurring between study drug initiation and end of study. This completed trial is registered with the Pan African Clinical Trials Registry (PACTR202007806554538)., Findings: Between Aug 18, 2021, and Aug 18, 2022, 24 neonates were enrolled into the trial and received study drugs. Eight neonates completed stage 1, meeting interim pharmacokinetic and safety criteria. In stage 2, 16 neonates received study drugs. Geometric mean abacavir and lamivudine exposures (AUC
0-24 ) were higher at 6-14 days (51·7 mg × h/L for abacavir and 17·2 mg × h/L for lamivudine) than at 19-24 days of age (25·0 mg × h/L and 11·3 mg × h/L), whereas they were similar for lopinavir over this period (AUC 0-12 58·5 mg × h/L vs 46·4 mg × h/L). Abacavir geometric mean AUC0-24 crossed the upper reference range at pharmacokinetics 1, but rapidly decreased. Lamivudine and lopinavir AUC0-tau were within range. No grade 2 or worse adverse events were related to study drugs. One neonate had a grade 1 prolonged corrected QT interval using the Fridericia method that spontaneously resolved., Interpretation: Abacavir-lamivudine dispersible tablets and ritonavir-boosted lopinavir granules in neonates were safe and provided drug exposures similar to those in young infants. Although further safety data are needed, this regimen presents a new option for HIV prevention and treatment from birth. Accelerating neonatal pharmacokinetic studies of novel antiretroviral therapies is essential for neonates to also benefit from state-of-the-art treatments., Funding: Unitaid., Competing Interests: Declaration of interests All authors and their institutions received funding from Unitaid to do this study (except EVC). All authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
17. Hepatitis B prevalence and associated factors in adults presenting for infection screening in northern Thailand.
- Author
-
Salvadori N, Gauthier L, Guy M, Ngo-Giang-Huong N, Khamduang W, Decker L, Achalapong J, Mary JY, Sirirungsi W, Pornprasert S, Arunothong S, Ongwandee S, and Jourdain G
- Abstract
Background and Aims: Hepatitis B is a leading cause of morbidity and mortality worldwide. In view of the World Health Organization 2030 targets, effective screening of chronic infection is crucial. We have assessed the prevalence and risk factors of hepatitis B surface antigen in adults presenting for screening., Methods: Free-of-charge and anonymous services for simultaneous hepatitis B, hepatitis C, human immunodeficiency virus and syphilis screening and counseling were provided in four facilities in northern Thailand. Analyses were performed separately in clients born before integration into the 1992 hepatitis B vaccine Thailand's Expanded Program on Immunization and in clients born afterwards., Results: Between October 2015 and August 2020, hepatitis B surface antigen prevalence was 7.2 % (185/2578) in clients born before 1992 (95 % confidence interval [CI] = 6.2%-8.2 %). In the multivariable analysis, characteristics independently associated with a higher risk of infection were being born male (adjusted odds ratio [aOR] = 1.49, 95 % CI = 1.10-2.01) and being part of a hill tribe (aOR = 1.65, 95 % CI = 1.01-2.70). Forty-two percent were unaware of their infection. In clients born in 1992 or afterwards, prevalence was 1.5 % (43/2933) (95 % CI = 1.1%-2.0 %) and characteristics independently associated with a higher risk were being born between 1992 and 1995 (aOR = 1.90, 95 % CI = 1.00-3.61), being born male (aOR = 2.60, 95 % CI = 1.34-5.07), being part of a hill tribe (aOR = 5.09, 95 % CI = 2.52-10.26) and having ever injected drugs (aOR = 4.33, 95 % CI = 1.23-15.24)., Conclusions: Risk factor-based screening would miss many chronic hepatitis cases. Screening all adults once in their lifetime may be beneficial until the second generation of immunized infants have reached adult age., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
18. CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment.
- Author
-
Paolini Paoletti F, Gaetani L, Bellomo G, Chipi E, Salvadori N, Montanucci C, Mancini A, Filidei M, Nigro P, Simoni S, Tambasco N, Di Filippo M, and Parnetti L
- Abstract
Pathophysiological substrate(s) and progression of Parkinson's disease (PD) with mild cognitive impairment (PD-MCI) are still matter of debate. Baseline cerebrospinal fluid (CSF) neurochemical profile and cognitive changes after 2 years were investigated in a retrospective series of PD-MCI (n = 48), cognitively normal PD (PD-CN, n = 40), prodromal Alzheimer's disease (MCI-AD, n = 25) and cognitively healthy individuals with other neurological diseases (OND, n = 44). CSF biomarkers reflecting amyloidosis (Aβ42/40 ratio, sAPPα, sAPPβ), tauopathy (p-tau), neurodegeneration (t-tau, NfL, p-NfH), synaptic damage (α-syn, neurogranin) and glial activation (sTREM2, YKL-40) were measured. The great majority (88%) of PD-MCI patients was A-/T-/N-. Among all biomarkers considered, only NfL/p-NfH ratio was significantly higher in PD-MCI vs. PD-CN (p = 0.02). After 2 years, one-third of PD-MCI patients worsened; such worsening was associated with higher baseline levels of NfL, p-tau, and sTREM2. PD-MCI is a heterogeneous entity requiring further investigations on larger, longitudinal cohorts with neuropathological verification., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
19. Repeatable Battery for the Assessment of Neuropsychological Status: Italian Normative Data for Older Adults.
- Author
-
Chipi E, Fruttini D, Salvadori N, Montanucci C, Siena E, Menculini G, Mazzeschi C, and Parnetti L
- Subjects
- Humans, Aged, Middle Aged, Neuropsychological Tests, Cognition, Regression Analysis, Cognitive Dysfunction diagnosis, Cognitive Dysfunction psychology, Cognition Disorders diagnosis
- Abstract
Objective: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), widely used for detecting cognitive impairment in different neuropsychiatric conditions, is increasingly applied for measuring cognitive functioning in older individuals. Available normative data for RBANS Italian version suffer from under-representation of the older ages (>60 years) and are not corrected for education. Moreover, normative data are provided only for Indexes and Total scores. We thus administered RBANS Italian version in a larger sample of older adults, taking into account the effect of age, education and gender on all scores., Method: We used a regression-based model to assess the effect of age, education, and gender on RBANS Subtests, Indexes and Total scores in a consecutive series of healthy cognitively normal volunteers aged 60-79 years (N = 158). The obtained norms were compared with the Italian original normative data by means of Wilcoxon rank-sum test., Results: Multiple linear regression analyses showed that age and educational level significantly influence performances on most RBANS scores. A free-to-use Excel to calculate subject's percentiles for any single score was developed. When compared with original normative values, our percentiles distribution of Indexes and Total scores did not reveal significant differences (p > .05)., Conclusion: The obtained normative data show good concordance with previous norms. The instrument seems not significantly affected by educational level. The possibility to correct for any single score could make RBANS a more precise measure for capturing subtle cognitive deficits in prevention studies., (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
20. Clinical correlates of state and trait anxiety in multiple sclerosis.
- Author
-
Menculini G, Gentili L, Gaetani L, Mancini A, Sperandei S, Di Sabatino E, Chipi E, Salvadori N, Tortorella A, Parnetti L, and Di Filippo M
- Subjects
- Humans, Female, Depression complications, Quality of Life, Anxiety complications, Anxiety Disorders complications, Multiple Sclerosis complications, Multiple Sclerosis epidemiology, Multiple Sclerosis psychology
- Abstract
Background: Anxiety represents one of the most prevalent psychiatric symptoms in multiple sclerosis (MS), impacting the overall disease burden and quality of life. This psychopathological feature can be expressed as state (S-ANX) and trait (T-ANX) anxiety, but few studies specifically evaluated these two components in MS. The present study was aimed at investigating the prevalence and specific correlates of S-ANX and T-ANX in a cohort of people with MS (PwMS)., Methods: 88 in- and out-patients with MS were consecutively recruited. S-ANX and T-ANX were evaluated with the two subscales of the State and Trait Anxiety Inventory. Bivariate analyses were performed to compare PwMS who displayed clinically significant S-ANX and T-ANX and those who did not. Two logistic regression models were run in order to identify variables significantly associated with S-ANX and T-ANX., Results: S-ANX and T-ANX presented a prevalence of 42% and 45.5%, respectively. S-ANX was more frequent in subjects hospitalized due to recent MS onset. PwMS and S-ANX more frequently had a recent relapse, as well as evidence of disease activity on brain magnetic resonance imaging. Subjects with T-ANX were more often females and displayed higher severity of fatigue. Depressive features at the Beck Depression Inventory were more severe in both S-ANX and T-ANX subjects. PwMS with S-ANX reported a higher prevalence of T-ANX and vice versa. At the logistic regressions, depression severity displayed a significant association with S-ANX and T-ANX. We also detected positive associations between S-ANX and inpatient status, as well as between T-ANX and female sex., Conclusion: Both S-ANX and T-ANX are highly prevalent features in PwMS. These two components of anxiety should be adequately identified and discriminated in the clinical practice. The higher severity of depression in PwMS with clinically significant anxiety should not be neglected., Competing Interests: Declaration of interests LGe, SS, EDS, EC, NS, and LP have no conflicts of interest to declare. GM received travel grants from Janssen (unrelated to the present work). LGa participated on advisory boards for, and received writing honoraria and travel grants from Almirall, Biogen, Euroimmun, Fujirebio, Merck, Mylan, Novartis, Roche, Sanofi, and Teva. AM received travel grants and writing honoraria from Almirall, Biogen, Merck, Mylan, Novartis, Sanofi Genzyme, and Teva. AT received research support from Lundbeck and served as speaker for Lundbeck and Angelini (unrelated to the present work). MDF participated on advisory boards for and received speaker or writing honoraria, research support and funding for travelling from Bayer, Biogen Idec, Genzyme, Merck, Mylan, Novartis, Roche, Siemens Healthineers, Teva and Viatris., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
21. Uptake, acceptability and interpretability of 3-in-1 rapid blood self-testing for HIV, hepatitis B and hepatitis C.
- Author
-
Salvadori N, Achalapong J, Boontan C, Piriya C, Arunothong S, Nangola S, Kloypan C, Prompunt E, Khamduang W, Moolnoi P, Pornprasert S, Ongwandee S, Mary JY, Jourdain G, and Ngo-Giang-Huong N
- Subjects
- Humans, Female, Adult, Hepatitis B Surface Antigens, Self-Testing, Hepacivirus, HIV Antibodies, Hepatitis C Antibodies, HIV Infections diagnosis, HIV Infections epidemiology, Hepatitis B diagnosis, Hepatitis B epidemiology, Hepatitis C diagnosis, Hepatitis C epidemiology, HIV-1
- Abstract
Introduction: Early diagnosis is key to achieving the goal of eliminating transmission of HIV and hepatitis B and C. We assessed the uptake, acceptability and interpretability of self-testing using a 3-in-1 rapid diagnostic test (RDT) in facility-based services., Methods: Stand-alone testing services were provided free of charge to consenting individuals aged ≥15 years in five facilities in northern Thailand. Clients were invited to choose between self-testing by fingerprick or venepuncture by a healthcare worker (HCW). In each facility, several clients could simultaneously self-test in separate private areas using TriQuik™ (Genlantis, San Diego, CA, USA), a single immunochromatographic cassette detecting HIV-1/2 antibody, hepatitis B surface antigen (HBsAg) and hepatitis C antibody (HCAb). An interactive program on a tablet computer was developed to collect socio-demographic, behavioural and satisfaction data and provide information to guide the self-test process, including video instructions, results interpretation and a picture of the cassette for immediate remote review by the HCW. When the HCW interpreted an HIV self-test as positive, the HCW collected blood by venepuncture for immediate confirmation., Results: Between October 2020 and April 2022, 4119 clients presented for testing for the first time as part of the project. Of them, 3462 (84.0%) opted for self-testing. Among self-testers, 1801 (52.0%) were born female, the median age was 27 years (interquartile range, 22-36), 661 (19.1%) belonged to at least one key population and 2124 (61.4%) had never been tested for HIV; 3329 (99.8% of those who answered) reported being "very satisfied" or "satisfied" with the testing process. The proportions of test results interpreted as positive by self-testers among those interpreted as positive by HCWs were 95% for HIV-1/2 antibody, 95% for HBsAg and 78% for HCAb., Conclusions: These proportions were higher than those observed in a previous study evaluating another 3-in-1 RDT for HIV, HBsAg and HCAb, possibly due to the use of video instructions instead of paper-based instructions, lower prevalence and co-infection rates, or lower percentages of clients with low education level. Multiplex self-testing simplified and streamlined the service delivery process and was well accepted. HCW assistance proved to be essential in a limited number of cases., (© 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.)
- Published
- 2022
- Full Text
- View/download PDF
22. Chronic Kidney Disease in a Large National Human Immunodeficiency Virus Treatment Program.
- Author
-
Paengsai N, Noppakun K, Jourdain G, Cressey TR, Salvadori N, Chaiwarith R, Tantraworasin A, Mary JY, Bowonwatanuwong C, Bhakeecheep S, Traisathit P, and Kosachunhanun N
- Abstract
Tenofovir disoproxil fumarate (TDF) is associated with a risk of chronic kidney disease (CKD), especially in Asian populations. Data from the Thai national health insurance system was used to assess CKD incidence in patients receiving antiretroviral therapy in real-world practice. We analyzed data from patients who initiated one of the following first-line regimens: zidovudine + lamivudine + nevirapine (AZT + 3TC + NVP); zidovudine + lamivudine + efavirenz (AZT + 3TC + EFV); tenofovir + lamivudine + nevirapine (TDF + 3TC + NVP); tenofovir + lamivudine/emtricitabine + efavirenz (TDF + 3TC/FTC + EFV); and tenofovir +lamivudine +lopinavir/ritonavir (TDF + 3TC + LPV/r). CKD was defined as glomerular filtration rate <60 mL/min/1.73 m2 for >3 months, or a confirmed 2010 WHO diagnosis (ICD-10 code N183, N184, or N185). Death competing risk survival regression models were used. Among 27,313 participants, with a median age of 36.8 years and median follow-up of 2.3 years, 245 patients (0.9%) were diagnosed with CKD (incidence 3.2 per 1000 patient-years; 95% CI 2.8−3.6). Compared with patients receiving AZT + 3TC + NVP, the risk of CKD measured by adjusted sub-distribution hazard ratio (aSHR) was 6.5 (95% CI 3.9−11.1) in patients on TDF + 3TC + LPV/r, 3.8 (95% CI 2.3−6.0) in TDF + 3TC + NVP, and 1.6 (95% CI 1.2−2.3) in TDF + 3TC/FTC + EFV. Among patients receiving TDF, compared with those receiving TDF + 3TC/FTC + EFV, the aSHR was 4.0 (95% CI 2.3−6.8) in TDF + 3TC + LPV/r and 2.3 (95% CI 1.4−3.6) in TDF + 3TC + NVP. TDF was associated with an increased risk of CKD, especially when combined with LPV/r or NVP.
- Published
- 2022
- Full Text
- View/download PDF
23. Proximal tubular dysfunction in pregnant women receiving tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virus.
- Author
-
Liegeon G, Ngo-Giang-Huong N, Salvadori N, Bunpo P, Cressey R, Achalapong J, Kanjanavikai P, Patamasingh Na Ayudhaya O, Prommas S, Siriwachirachai T, Sabsanong P, Yves Mary J, and Jourdain G
- Subjects
- Antiviral Agents therapeutic use, Child, Preschool, Female, Humans, Infant, Infectious Disease Transmission, Vertical prevention & control, Pregnancy, Pregnant Women, Tenofovir adverse effects, Hepatitis B virus, Pregnancy Complications, Infectious drug therapy, Pregnancy Complications, Infectious prevention & control
- Abstract
Background: Data evaluating the risk of proximal tubular dysfunction in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission (PMTCT) of HBV are scarce., Objectives: To assess the risk of proximal tubulopathy in pregnant women receiving tenofovir disoproxil fumarate for PMTCT of HBV., Patients and Methods: We used urine samples collected from HBV monoinfected pregnant women who participated in a Phase III, multicentre, randomized, double-blind, placebo-controlled clinical trial assessing a tenofovir disoproxil fumarate short course from 28 weeks gestational age (28-wk-GA) to 2 months post-partum (2-months-PP) for PMTCT of HBV in Thailand. Markers of tubular dysfunction, including retinol binding protein, kidney injury molecule-1, α1-microglobuin and β2-microglobulin, were assayed at 28- and 32-wk-GA and 2-months-PP visits. Proximal tubulopathy was defined as the presence of ≥2 of the following: tubular proteinuria, euglycaemic glycosuria and increased urinary phosphate., Results: A total of 291 women participated in the study. No kidney-related adverse events were severe, and none led to tenofovir disoproxil fumarate discontinuation. At 2-months-PP, 3 of the 120 (3%) evaluated women in the tenofovir disoproxil fumarate group experienced proximal tubulopathy versus 3 of 125 (2%) in the placebo group (P = 1.00). None of the six women met the criteria for proximal tubulopathy at 12-months-PP but proteinuria persisted in three of them. No growth abnormalities were found at 1 year of age in infants born to mothers with proximal tubulopathy at 2-months-PP., Conclusions: In these HBV-infected pregnant and breastfeeding women, tenofovir disoproxil fumarate administered from 28-wk-GA to 2-months-PP was not associated with a higher risk of proximal tubulopathy., (© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
24. Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study.
- Author
-
Bekker A, Rabie H, Salvadori N, du Toit S, Than-In-At K, Groenewald M, Andrieux-Meyer I, Kumar M, Cressey R, Nielsen J, Capparelli E, Lallemant M, Cotton MF, and Cressey TR
- Subjects
- Dideoxynucleosides, Drug Therapy, Combination adverse effects, Humans, Infant, Newborn, Lamivudine adverse effects, Lamivudine pharmacokinetics, Lopinavir adverse effects, Lopinavir pharmacokinetics, Ritonavir adverse effects, Ritonavir pharmacokinetics, Anti-HIV Agents adverse effects, Anti-HIV Agents pharmacokinetics, HIV Infections drug therapy
- Abstract
Background: Antiretroviral options for neonates (younger than 28 days) should be expanded. We evaluated the pharmacokinetics, safety, and acceptability of the "4-in-1" fixed-dose pediatric granule formulation of abacavir/lamivudine/lopinavir/ritonavir (30/15/40/10 mg) in neonates., Methods: The PETITE study is an ongoing phase I/II, open-label, single-arm, 2-stage trial conducted in South Africa. In stage 1, term neonates exposed to HIV on standard antiretroviral prophylaxis (nevirapine ± zidovudine) received single dose(s) of the 4-in-1 formulation, followed by intensive pharmacokinetic sampling and safety assessments. At each PK visit, blood was drawn after an observed dose at 1, 2, 4, 8, and 12 hours postdose. In this study, we have reported the planned interim pharmacokinetic and safety analysis after completion of the single-dose administration., Results: Sixteen neonates, with a median (range) birth weight of 3130 g (2790-3590 g), completed 24 pharmacokinetic visits. The 4-in-1 formulation imposed relatively high doses of abacavir [8.6 mg/kg (6.6-11.4)] and lamivudine [4.3 mg/kg (3.3-5.7)] but lower doses of lopinavir [11.5 mg/kg (8.8-15.2)]. The geometric means (GM, 90% CI) AUC0-12 of abacavir, lamivudine, and lopinavir were 29.87 (26.29-33.93), 12.61 (10.72-14.83), and 3.49 (2.13-5.72) µg.h/mL, respectively. Lopinavir GM AUC0-12 was below the predefined target (20-100 µg.h/mL), and ritonavir concentrations were only detectable in 4 of the 120 (3%) samples. No adverse events were related to study drugs. No neonate had difficulty swallowing the 4-in-1 formulation., Conclusions: The high doses of abacavir and lamivudine (in mg/kg) and AUCs were safe, and the formulation was well tolerated; however, lopinavir/ritonavir exposures were extremely low, preventing its use in neonates use in neonates. Alternative pediatric solid antiretroviral formulations must be studied in neonates., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
25. Clinical and Instrumental Characterization of Patients With Late-Onset Epilepsy.
- Author
-
DiFrancesco JC, Labate A, Romoli M, Chipi E, Salvadori N, Galimberti CA, Perani D, Ferrarese C, and Costa C
- Abstract
Epilepsy is classically considered a childhood disease. However, it represents the third most frequent neurological condition in the elderly, following stroke, and dementia. With the progressive aging of the general population, the number of patients with Late-Onset Epilepsy (LOE) is constantly growing, with important economic and social consequences, in particular for the more developed countries where the percentage of elderly people is higher. The most common causes of LOE are structural, mainly secondary to cerebrovascular or infectious diseases, brain tumors, trauma, and metabolic or toxic conditions. Moreover, there is a growing body of evidence linking LOE with neurodegenerative diseases, particularly Alzheimer's disease (AD). However, despite a thorough characterization, the causes of LOE remain unknown in a considerable portion of patients, thus termed as Late-Onset Epilepsy of Unknown origin (LOEU). In order to identify the possible causes of the disease, with an important impact in terms of treatment and prognosis, LOE patients should always undergo an exhaustive phenotypic characterization. In this work, we provide a detailed review of the main clinical and instrumental techniques for the adequate characterization of LOE patients in the clinical practice. This work aims to provide an easy and effective tool that supports routine activity of the clinicians facing LOE., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 DiFrancesco, Labate, Romoli, Chipi, Salvadori, Galimberti, Perani, Ferrarese and Costa.)
- Published
- 2022
- Full Text
- View/download PDF
26. Zika Virus Immunoglobulin G Seroprevalence among Young Adults Living with HIV or without HIV in Thailand from 1997 to 2017.
- Author
-
Choyrum S, Wangsaeng N, Nechba A, Salvadori N, Saisom R, Achalapong J, Putiyanun C, Sabsanong P, Sangsawang S, Patamasingh Na Ayudhaya O, Jourdain G, Ngo-Giang-Huong N, and Khamduang W
- Subjects
- Enzyme-Linked Immunosorbent Assay, Female, HIV Infections epidemiology, HIV-1 genetics, Humans, Logistic Models, Male, Pregnancy, Pregnant Women, Retrospective Studies, Seroepidemiologic Studies, Thailand epidemiology, Young Adult, Zika Virus Infection diagnosis, Antibodies, Viral blood, HIV Infections complications, Immunoglobulin G blood, Zika Virus immunology, Zika Virus Infection epidemiology
- Abstract
Zika virus (ZIKV) epidemiological data in Thailand are limited. We assessed ZIKV IgG seroprevalence among young adults during 1997-2017 and determined factors associated with ZIKV IgG seropositivity. This retrospective laboratory study included randomly selected subjects aged 18-25 years participating in large clinical studies conducted in Thailand during 1997-2017. Stored plasma samples were analyzed for ZIKV IgG using an ELISA test (Anti-Zika Virus IgG, EUROIMMUN, Lübeck, Germany). Sociodemographic, clinical and laboratory data were used in univariable and multivariable analyses to identify factors associated with ZIKV IgG positivity. Of the 1648 subjects included, 1259 were pregnant women, 844 were living with HIV and 111 were living with HBV. ZIKV IgG seroprevalence was similar among the HIV-infected and -uninfected pregnant women (22.8% vs. 25.8%, p -value = 0.335) and was overall stable among the pregnant women, with a 25.2% prevalence. Factors independently associated with ZIKV IgG positivity included an age of 23-25 years as compared to 18-20 years, an HIV RNA load below 3.88 log
10 copies/mL and birth in regions outside northern Thailand. Our study shows that a large proportion of the population in Thailand probably remains susceptible to ZIKV infection, which could be the ground for future outbreaks. Continued surveillance of ZIKV spread in Thailand is needed to inform public health policies.- Published
- 2022
- Full Text
- View/download PDF
27. Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis.
- Author
-
Di Filippo M, Mancini A, Bellingacci L, Gaetani L, Mazzocchetti P, Zelante T, La Barbera L, De Luca A, Tantucci M, Tozzi A, Durante V, Sciaccaluga M, Megaro A, Chiasserini D, Salvadori N, Lisetti V, Portaccio E, Costa C, Sarchielli P, Amato MP, Parnetti L, Viscomi MT, Romani L, and Calabresi P
- Subjects
- Animals, CA1 Region, Hippocampal pathology, CA1 Region, Hippocampal physiopathology, Encephalomyelitis, Autoimmune, Experimental pathology, Encephalomyelitis, Autoimmune, Experimental physiopathology, Encephalomyelitis, Autoimmune, Experimental psychology, Interleukin-17 genetics, Long-Term Potentiation, Male, Mice, Biozzi, Mice, Inbred C57BL, Mice, Knockout, Receptors, Interleukin-17 genetics, Signal Transduction, Spatial Learning, Synapses pathology, p38 Mitogen-Activated Protein Kinases, Mice, Behavior, Animal, CA1 Region, Hippocampal metabolism, Cognition, Encephalomyelitis, Autoimmune, Experimental metabolism, Interleukin-17 metabolism, Neuronal Plasticity, Receptors, Interleukin-17 metabolism, Synapses metabolism
- Abstract
Cognitive impairment (CI) is a disabling concomitant of multiple sclerosis (MS) with a complex and controversial pathogenesis. The cytokine interleukin-17A (IL-17A) is involved in the immune pathogenesis of MS, but its possible effects on synaptic function and cognition are still largely unexplored. In this study, we show that the IL-17A receptor (IL-17RA) is highly expressed by hippocampal neurons in the CA1 area and that exposure to IL-17A dose-dependently disrupts hippocampal long-term potentiation (LTP) through the activation of its receptor and p38 mitogen-activated protein kinase (MAPK). During experimental autoimmune encephalomyelitis (EAE), IL-17A overexpression is paralleled by hippocampal LTP dysfunction. An in vivo behavioral analysis shows that visuo-spatial learning abilities are preserved when EAE is induced in mice lacking IL-17A. Overall, this study suggests a key role for the IL-17 axis in the neuro-immune cross-talk occurring in the hippocampal CA1 area and its potential involvement in synaptic dysfunction and MS-related CI., Competing Interests: Declaration of interests M.D.F. participated on advisory boards for and received speaker or writing honoraria and funding for traveling from Bayer, Biogen Idec, Genzyme, Merck, Mylan, Novartis, Roche, and Teva. A. Mancini received speaker or writing honoraria and travel grants to attend national and international conferences from Almirall, Biogen Idec, Merck, Mylan, Novartis, Sanofi, and Teva. L.G. participated on advisory boards for and received speaker or writing honoraria and funding for traveling from Almirall, Biogen, Biogen-Idec, Genzyme, Mylan, Novartis, Roche, and Teva. E.P. served on scientific advisory board for Biogen Idec and Merck Serono and received honoraria for speaking and funding for traveling from Biogen, Genzyme, Novartis, Merck, and Teva. M.P.A. participated on advisory boards for and received speaker honoraria and research funding from Bayer, Biogen Idec, Sanofi Genzyme, Merck, Novartis, Roche, and Teva. P.C. received/receives research support from Bayer Schering, Biogen-Dompé, Boehringer Ingelheim, Eisai, Lundbeck, Merck-Serono, Novartis, Sanofi-Aventis, Sigma-Tau, and UCB Pharma. P.M., T.Z., A.L., M.T., A. Megaro, L.B., M.S., A.T., V.D., D.C., N.S., V.L., C.C., L.P., M.T.V., L.L.B., P.S., and L.R. declare no competing interests., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
28. Lack of Association between Adverse Pregnancy Outcomes and Zika Antibodies among Pregnant Women in Thailand between 1997 and 2015.
- Author
-
Ngo-Giang-Huong N, Leroi C, Fusco D, Cressey TR, Wangsaeng N, Salvadori N, Kongyai N, Sirirungsi W, Lallemant M, Auewarakul P, Khamduang W, and Jourdain G
- Subjects
- Adult, Case-Control Studies, Dengue Virus immunology, Female, Humans, Immunoglobulin G blood, Immunoglobulin M blood, Infant, Infant, Newborn, Microcephaly epidemiology, Pregnancy, Seroepidemiologic Studies, Stillbirth, Thailand epidemiology, Antibodies, Viral blood, Pregnancy Complications, Infectious epidemiology, Pregnancy Outcome, Zika Virus immunology, Zika Virus Infection epidemiology
- Abstract
Data about Zika virus infection and adverse pregnancy outcomes in Southeast Asia are scarce. We conducted an unmatched case-control study of Zika virus (ZIKV) serology in pregnant women enrolled in human immunodeficiency virus (HIV) or hepatitis B virus (HBV) perinatal prevention trials between 1997 and 2015 in Thailand. Case and control groups included women with and without adverse pregnancy outcomes. Plasma samples collected during the last trimester of pregnancy were tested for ZIKV IgG/IgM and Dengue IgG/IgM (Euroimmun, AG, Germany). Case newborn plasma samples were tested for ZIKV IgM and ZIKV RNA (Viasure, Spain). The case group included women with stillbirth ( n = 22) or whose infants had microcephaly ( n = 4), a head circumference below the first percentile ( n = 14), neurological disorders ( n = 36), or had died within 10 days after birth ( n = 11). No women in the case group were positive for ZIKV IgM, and none of their live-born neonates were positive for ZIKV IgM or ZIKV RNA. The overall ZIKV IgG prevalence was 29%, 24% in the case and 34% in the control groups (Fisher's exact test; p = 0.13), while the dengue IgG seroprevalence was 90%. Neither neonatal ZIKV infections nor ZIKV-related adverse pregnancy outcomes were observed in these women with HIV and/or HBV during the 18-year study period.
- Published
- 2021
- Full Text
- View/download PDF
29. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.
- Author
-
Andrieux-Meyer I, Tan SS, Thanprasertsuk S, Salvadori N, Menétrey C, Simon F, Cressey TR, Said HRHM, Hassan MRA, Omar H, Tee HP, Chan WK, Kumar S, Thongsawat S, Thetket K, Avihingsanon A, Khemnark S, Yerly S, Ngo-Giang-Huong N, Siva S, Swanson A, Goyal V, Bompart F, Pécoul B, and Murad S
- Subjects
- Adult, Aged, Antiviral Agents administration & dosage, Antiviral Agents adverse effects, Antiviral Agents therapeutic use, Benzimidazoles administration & dosage, Benzimidazoles adverse effects, Coinfection epidemiology, Drug Therapy, Combination, Female, Genotype, HIV Infections complications, HIV Infections drug therapy, Hepacivirus drug effects, Hepacivirus genetics, Hepatitis C, Chronic complications, Hepatitis C, Chronic virology, Humans, Liver Cirrhosis drug therapy, Liver Cirrhosis epidemiology, Liver Cirrhosis etiology, Malaysia epidemiology, Male, Middle Aged, RNA, Viral drug effects, Safety, Sofosbuvir administration & dosage, Sofosbuvir adverse effects, Sustained Virologic Response, Thailand epidemiology, Treatment Outcome, Valine administration & dosage, Valine adverse effects, Valine therapeutic use, Benzimidazoles therapeutic use, Hepatitis C, Chronic drug therapy, Sofosbuvir therapeutic use, Valine analogs & derivatives, Viral Nonstructural Proteins antagonists & inhibitors
- Abstract
Background: In low-income and middle-income countries, affordable direct-acting antivirals are urgently needed to treat hepatitis C virus (HCV) infection. The combination of ravidasvir, a pangenotypic non-structural protein 5A (NS5A) inhibitor, and sofosbuvir has shown efficacy and safety in patients with chronic HCV genotype 4 infection. STORM-C-1 trial aimed to assess the efficacy and safety of ravidasvir plus sofosbuvir in a diverse population of adults chronically infected with HCV., Methods: STORM-C-1 is a two-stage, open-label, phase 2/3 single-arm clinical trial in six public academic and non-academic centres in Malaysia and four public academic and non-academic centres in Thailand. Patients with HCV with compensated cirrhosis (Metavir F4 and Child-Turcotte-Pugh class A) or without cirrhosis (Metavir F0-3) aged 18-69 years were eligible to participate, regardless of HCV genotype, HIV infection status, previous interferon-based HCV treatment, or source of HCV infection. Once daily ravidasvir (200 mg) and sofosbuvir (400 mg) were prescribed for 12 weeks for patients without cirrhosis and for 24 weeks for those with cirrhosis. The primary endpoint was sustained virological response at 12 weeks after treatment (SVR12; defined as HCV RNA <12 IU/mL in Thailand and HCV RNA <15 IU/mL in Malaysia at 12 weeks after the end of treatment). This trial is registered with ClinicalTrials.gov, number NCT02961426, and the National Medical Research Register of Malaysia, NMRR-16-747-29183., Findings: Between Sept 14, 2016, and June 5, 2017, 301 patients were enrolled in stage one of STORM-C-1. 98 (33%) patients had genotype 1a infection, 27 (9%) had genotype 1b infection, two (1%) had genotype 2 infection, 158 (52%) had genotype 3 infection, and 16 (5%) had genotype 6 infection. 81 (27%) patients had compensated cirrhosis, 90 (30%) had HIV co-infection, and 99 (33%) had received previous interferon-based treatment. The most common treatment-emergent adverse events were pyrexia (35 [12%]), cough (26 [9%]), upper respiratory tract infection (23 [8%]), and headache (20 [7%]). There were no deaths or treatment discontinuations due to serious adverse events related to study drugs. Of the 300 patients included in the full analysis set, 291 (97%; 95% CI 94-99) had SVR12. Of note, SVR12 was reported in 78 (96%) of 81 patients with cirrhosis and 153 (97%) of 158 patients with genotype 3 infection, including 51 (96%) of 53 patients with cirrhosis. There was no difference in SVR12 rates by HIV co-infection or previous interferon treatment., Interpretation: In this first stage, ravidasvir plus sofosbuvir was effective and well tolerated in this diverse adult population of patients with chronic HCV infection. Ravidasvir plus sofosbuvir has the potential to provide an additional affordable, simple, and efficacious public health tool for large-scale implementation to eliminate HCV as a cause of morbidity and mortality., Funding: National Science and Technology Development Agency, Thailand; Department of Disease Control, Ministry of Public Health, Thailand; Ministry of Health, Malaysia; UK Aid; Médecins Sans Frontières (MSF); MSF Transformational Investment Capacity; FIND; Pharmaniaga; Starr International Foundation; Foundation for Art, Research, Partnership and Education; and the Swiss Agency for Development and Cooperation., (Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
30. Temporal lobe dysfunction in late-onset epilepsy of unknown origin.
- Author
-
DiFrancesco JC, Isella V, Licciardo D, Crivellaro C, Musarra M, Guerra L, Salvadori N, Chipi E, Calvello C, Costa C, and Ferrarese C
- Subjects
- Adult, Electroencephalography, Fluorodeoxyglucose F18, Humans, Magnetic Resonance Imaging, Positron-Emission Tomography, Retrospective Studies, Temporal Lobe, Tomography, X-Ray Computed, Epilepsy, Epilepsy, Temporal Lobe complications, Epilepsy, Temporal Lobe diagnostic imaging
- Abstract
Objective: Epilepsy with onset in the adulthood is an increasing health problem, due to the progressive aging of the worldwide population. Whether the causes remain undetermined, the disease is defined as Late-Onset Epilepsy of Unknown origin (LOEU). The aim of this study was to evaluate the semiological, electroencephalographic, metabolic, and neuropsychological features of LOEU., Methods: We selected patients with late-onset epilepsy (LOE) (≥55 years), whose causes of the disease have been excluded with a deep clinical-instrumental characterization, including brain MRI, EEG,
18 F-labeled fluoro-2-deoxyglucose positron emission tomography (FDG-PET), and neuropsychological assessment., Results: Twenty-three LOEU cases were retrospectively recruited. Half presented focal-onset seizures (FOS), the others focal to bilateral tonic-clonic seizures (FBTCS). All demonstrated a mild phenotype, with no recurrence of seizures on single antiseizure treatment at prolonged follow-up. Brain MRI scans were normal in 12 patients (52.3%) and showed nonspecific gliosis or mild atrophy in ten (43.5%); hippocampal sclerosis (HS) was observed in one. In 17/23 (73.9%), the EEG showed slow and/or epileptiform activity of the temporal areas. Brain FDG-PET revealed temporal lobe hypometabolism, mostly ipsilateral to EEG abnormal activity, or multifocal temporal and extra-temporal (cortical, subcortical and subtentorial) clusters of hypometabolism. The neuropsychological analysis demonstrated three different profiles: normal (43.5%), with focal deficits (39.1%) or mild multidomain impairment (17.4%)., Significance: Late-Onset Epilepsy of Unknown origin can present as FOS or FBTCS, both with good prognosis. The application of metabolic imaging and neurophysiology techniques in these patients points to the dysfunction of the temporal structures, whose role in the pathogenetic process of the disease remains to be clarified., (Copyright © 2021 Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
31. Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers.
- Author
-
Gaetani L, Salvadori N, Chipi E, Gentili L, Borrelli A, Parnetti L, and Di Filippo M
- Abstract
Cognitive impairment is a common clinical manifestation of multiple sclerosis, but its pathophysiology is not completely understood. White and grey matter injury together with synaptic dysfunction do play a role. The measurement of biomarkers in the cerebrospinal fluid and the study of their association with cognitive impairment may provide interesting in vivo evidence of the biological mechanisms underlying multiple sclerosis-related cognitive impairment. So far, only a few studies on this topic have been published, giving interesting results that deserve further investigation. Cerebrospinal fluid biomarkers of different pathophysiological mechanisms seem to reflect different neuropsychological patterns of cognitive deficits in multiple sclerosis. The aim of this review is to discuss the studies that have correlated cerebrospinal fluid markers of immune, glial and neuronal pathology with cognitive impairment in multiple sclerosis. Although preliminary, these findings suggest that cerebrospinal fluid biomarkers show some correlation with cognitive performance in multiple sclerosis, thus providing interesting insights into the mechanisms underlying the involvement of specific cognitive domains., Competing Interests: LGa participated on advisory boards for, and received writing honoraria and travel grants from Almirall, Biogen, Merck, Mylan, Novartis, Roche, Sanofi Genzyme and Teva. MDF participated on advisory boards for and received speaker or writing honoraria and funding for travelling from Bayer, Biogen Idec, Genzyme, Merck, Mylan, Novartis, Roche and Teva. Others report no conflict of interest
- Published
- 2021
- Full Text
- View/download PDF
32. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
- Author
-
van Waalwijk van Doorn LJC, Ghafoorian M, van Leijsen EMC, Claassen JAHR, Arighi A, Bozzali M, Cannas J, Cavedo E, Eusebi P, Farotti L, Fenoglio C, Fortea J, Frisoni GB, Galimberti D, Greco V, Herukka SK, Liu Y, Lleó A, de Mendonça A, Nobili FM, Parnetti L, Picco A, Pikkarainen M, Salvadori N, Scarpini E, Soininen H, Tarducci R, Urbani A, Vilaplana E, Meulenbroek O, Platel B, Verbeek MM, and Kuiperij HB
- Subjects
- Aged, Alzheimer Disease diagnosis, Cognitive Dysfunction diagnosis, Confounding Factors, Epidemiologic, Female, Humans, Image Processing, Computer-Assisted, Leukoencephalopathies diagnostic imaging, Magnetic Resonance Imaging, Male, Middle Aged, Phosphorylation, Alzheimer Disease cerebrospinal fluid, Amyloid beta-Peptides cerebrospinal fluid, Cognitive Dysfunction cerebrospinal fluid, Leukoencephalopathies cerebrospinal fluid, Peptide Fragments cerebrospinal fluid, tau Proteins cerebrospinal fluid
- Abstract
Background: The cerebrospinal fluid (CSF) biomarkers amyloid-β 1-42 (Aβ42), total and phosphorylated tau (t-tau, p-tau) are increasingly used to assist in the clinical diagnosis of Alzheimer's disease (AD). However, CSF biomarker levels can be affected by confounding factors., Objective: To investigate the association of white matter hyperintensities (WMHs) present in the brain with AD CSF biomarker levels., Methods: We included CSF biomarker and magnetic resonance imaging (MRI) data of 172 subjects (52 controls, 72 mild cognitive impairment (MCI), and 48 AD patients) from 9 European Memory Clinics. A computer aided detection system for standardized automated segmentation of WMHs was used on MRI scans to determine WMH volumes. Association of WMH volume with AD CSF biomarkers was determined using linear regression analysis., Results: A small, negative association of CSF Aβ42, but not p-tau and t-tau, levels with WMH volume was observed in the AD (r2 = 0.084, p = 0.046), but not the MCI and control groups, which was slightly increased when including the distance of WMHs to the ventricles in the analysis (r2 = 0.105, p = 0.025). Three global patterns of WMH distribution, either with 1) a low, 2) a peak close to the ventricles, or 3) a high, broadly-distributed WMH volume could be observed in brains of subjects in each diagnostic group., Conclusion: Despite an association of WMH volume with CSF Aβ42 levels in AD patients, the occurrence of WMHs is not accompanied by excess release of cellular proteins in the CSF, suggesting that WMHs are no major confounder for AD CSF biomarker assessment.
- Published
- 2021
- Full Text
- View/download PDF
33. Impact of Zika virus on the human type I interferon osteoimmune response.
- Author
-
Drouin A, Wallbillich N, Theberge M, Liu S, Katz J, Bellovoda K, Se Yun Cheon S, Gootkind F, Bierman E, Zavras J, Berberich MJ, Kalocsay M, Guastaldi F, Salvadori N, Troulis M, and Fusco DN
- Subjects
- Animals, Antiviral Agents pharmacology, Cell Line, Tumor, Chlorocebus aethiops, Gene Expression Regulation drug effects, Gene Expression Regulation immunology, Host-Pathogen Interactions drug effects, Host-Pathogen Interactions immunology, Humans, Interferon Type I pharmacology, Mice, Knockout, Osteoblasts metabolism, Osteoblasts virology, Proteome immunology, Proteome metabolism, Proteomics methods, Vero Cells, Virus Replication drug effects, Virus Replication immunology, Zika Virus physiology, Zika Virus Infection metabolism, Zika Virus Infection virology, Mice, Antiviral Agents immunology, Interferon Type I immunology, Osteoblasts immunology, Zika Virus immunology, Zika Virus Infection immunology
- Abstract
Background: The developing field of osteoimmunology supports importance of an interferon (IFN) response pathway in osteoblasts. Clarifying osteoblast-IFN interactions is important because IFN is used as salvage anti-tumor therapy but systemic toxicity is high with variable clinical results. In addition, osteoblast response to systemic bursts and disruptions of IFN pathways induced by viral infection may influence bone remodeling. ZIKA virus (ZIKV) infection impacts bone development in humans and IFN response in vitro. Consistently, initial evidence of permissivity to ZIKV has been reported in human osteoblasts., Hypothesis: Osteoblast-like Saos-2 cells are permissive to ZIKV and responsive to IFN., Methods: Multiple approaches were used to assess whether Saos-2 cells are permissive to ZIKV infection and exhibit IFN-mediated ZIKV suppression. Proteomic methods were used to evaluate impact of ZIKV and IFN on Saos-2 cells., Results: Evidence is presented confirming Saos-2 cells are permissive to ZIKV and support IFN-mediated suppression of ZIKV. ZIKV and IFN differentially impact the Saos-2 proteome, exemplified by HELZ2 protein which is upregulated by IFN but non responsive to ZIKV. Both ZIKV and IFN suppress proteins associated with microcephaly/pseudo-TORCH syndrome (BI1, KI20A and UBP18), and ZIKV induces potential entry factor PLVAP., Conclusions: Transient ZIKV infection influences osteoimmune state, and IFN and ZIKV activate distinct proteomes in Saos-2 cells, which could inform therapeutic, engineered, disruptions., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
34. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
- Author
-
Saddiki H, Fayosse A, Cognat E, Sabia S, Engelborghs S, Wallon D, Alexopoulos P, Blennow K, Zetterberg H, Parnetti L, Zerr I, Hermann P, Gabelle A, Boada M, Orellana A, de Rojas I, Lilamand M, Bjerke M, Van Broeckhoven C, Farotti L, Salvadori N, Diehl-Schmid J, Grimmer T, Hourregue C, Dugravot A, Nicolas G, Laplanche JL, Lehmann S, Bouaziz-Amar E, Hugon J, Tzourio C, Singh-Manoux A, Paquet C, and Dumurgier J
- Subjects
- Adult, Aged, Aged, 80 and over, Alzheimer Disease diagnosis, Biomarkers cerebrospinal fluid, Case-Control Studies, Cohort Studies, Female, Genotype, Humans, Male, Middle Aged, Aging cerebrospinal fluid, Aging genetics, Alzheimer Disease cerebrospinal fluid, Alzheimer Disease genetics, Apolipoprotein E4 cerebrospinal fluid, Apolipoprotein E4 genetics
- Abstract
Background: The ε4 allele of apolipoprotein E (APOE) gene and increasing age are two of the most important known risk factors for developing Alzheimer disease (AD). The diagnosis of AD based on clinical symptoms alone is known to have poor specificity; recently developed diagnostic criteria based on biomarkers that reflect underlying AD neuropathology allow better assessment of the strength of the associations of risk factors with AD. Accordingly, we examined the global and age-specific association between APOE genotype and AD by using the A/T/N classification, relying on the cerebrospinal fluid (CSF) levels of β-amyloid peptide (A, β-amyloid deposition), phosphorylated tau (T, pathologic tau), and total tau (N, neurodegeneration) to identify patients with AD., Methods and Findings: This case-control study included 1,593 white AD cases (55.4% women; mean age 72.8 [range = 44-96] years) with abnormal values of CSF biomarkers from nine European memory clinics and the American Alzheimer's Disease Neuroimaging Initiative (ADNI) study. A total of 11,723 dementia-free controls (47.1% women; mean age 65.6 [range = 44-94] years) were drawn from two longitudinal cohort studies (Whitehall II and Three-City), in which incident cases of dementia over the follow-up were excluded from the control population. Odds ratio (OR) and population attributable fraction (PAF) for AD associated with APOE genotypes were determined, overall and by 5-year age categories. In total, 63.4% of patients with AD and 22.6% of population controls carried at least one APOE ε4 allele. Compared with non-ε4 carriers, heterozygous ε4 carriers had a 4.6 (95% confidence interval 4.1-5.2; p < 0.001) and ε4/ε4 homozygotes a 25.4 (20.4-31.2; p < 0.001) higher OR of AD in unadjusted analysis. This association was modified by age (p for interaction < 0.001). The PAF associated with carrying at least one ε4 allele was greatest in the 65-70 age group (69.7%) and weaker before 55 years (14.2%) and after 85 years (22.6%). The protective effect of APOE ε2 allele for AD was unaffected by age. Main study limitations are that analyses were based on white individuals and AD cases were drawn from memory centers, which may not be representative of the general population of patients with AD., Conclusions: In this study, we found that AD diagnosis based on biomarkers was associated with APOE ε4 carrier status, with a higher OR than previously reported from studies based on only clinical AD criteria. This association differs according to age, with the strongest effect at 65-70 years. These findings highlight the need for early interventions for dementia prevention to mitigate the effect of APOE ε4 at the population level., Competing Interests: No conflicts of interest with regards to this paper. Outside the submitted work, TG reported having received consulting fees from Actelion, Biogen, Eli Lilly, Iqvia/ Quintiles; MSD; Novartis, Quintiles, Roche Pharma, lecture fees from Biogen, Lilly, Parexel, Roche Pharma, and grants to his institution from Actelion and PreDemTech.
- Published
- 2020
- Full Text
- View/download PDF
35. Impact of Counseling Methods on HIV Retesting Uptake in At-Risk Individuals: A Randomized Controlled Study.
- Author
-
Salvadori N, Decker L, Ngo-Giang-Huong N, Mary JY, Chevret S, Arunothong S, Adam P, Khamduang W, Samleerat T, Luangsook P, Suksa-Ardphasu V, Achalapong J, Rouzioux C, Sirirungsi W, and Jourdain G
- Subjects
- Counseling, Humans, Risk-Taking, Sexual Behavior, Thailand, HIV Infections diagnosis, HIV Infections prevention & control
- Abstract
Systematic face-to-face pre-HIV test counseling is costly and may discourage clients to present for regular testing. In a randomized, controlled, non-inferiority trial conducted in four facilities providing free-of-charge anonymous HIV testing in Thailand, participants received either: standard counseling according to national guidelines (reference); computer-assisted counseling: interactive counseling on a tablet computer followed by an invitation to ask questions to the counselor; or on-demand counseling: invitation to ask questions to the counselor. Primary endpoint was a HIV retest within 7 months after enrolment visit. Following the planned interim analysis, on-demand counseling was discontinued for futility. In the final analysis in 1036 HIV-uninfected at-risk participants, computer-assisted counseling was non-inferior to standard counseling and had similar acceptability and improvements in HIV knowledge and sexual risk behaviors; however, it significantly reduced the time spent by counselors on counseling. Implementation of pre-HIV test computer-assisted counseling may ease the burden on staff involved in HIV testing.
- Published
- 2020
- Full Text
- View/download PDF
36. Late-Onset Epilepsy With Unknown Etiology: A Pilot Study on Neuropsychological Profile, Cerebrospinal Fluid Biomarkers, and Quantitative EEG Characteristics.
- Author
-
Nardi Cesarini E, Babiloni C, Salvadori N, Farotti L, Del Percio C, Pascarelli MT, Noce G, Lizio R, Da Re F, Isella V, Tremolizzo L, Romoli M, DiFrancesco JC, Parnetti L, and Costa C
- Abstract
Introduction: Despite the fact that epilepsy has been associated with cognitive decline, neuropsychological, neurobiological, and neurophysiological features in patients with late-onset epilepsy of unknown etiology (LOEU) are still unknown. This cross-sectional study aims to investigate the neuropsychological profile, cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD), and resting-state quantitative electroencephalographic (qEEG) cortical rhythms in LOEU patients with mild cognitive impairment (LOEU-MCI) and with normal cognition (LOEU-CN), compared to non-epileptic MCI (NE-MCI) and cognitively normal (CN) controls. Methods: Consecutive patients in two clinical Units diagnosed with LOEU-CN (19), LOEU-MCI (27), and NE-MCI (21) were enrolled, and compared to age and sex-matched cognitively normal subjects CN (11). Patients underwent standardized comprehensive neuropsychological evaluation and CSF core AD biomarkers assessment (i.e., CSF Aβ42, phospho-tau and total tau, classified through A/T/(N) system). Recordings of resting-state eyes-closed electroencephalographic (EEG) rhythms were collected and cortical source estimation of delta (<4 Hz) to gamma (>30 Hz) bands with exact Low Resolution Electromagnetic Tomography (eLORETA) was performed. Results: Most LOEU patients had an MCI status at seizure onset (59%). Patients with LOEU-MCI performed significantly worse on measures of global cognition, visuo-spatial abilities, and executive functions compared to NE-MCI patients ( p < 0.05). Regarding MCI subtypes, multiple-domain MCI was 3-fold more frequent in LOEU-MCI than in NE-MCI patients (OR 3.14, 95%CI 0.93-10.58, p = 0.06). CSF Aβ42 levels were lower in the LOEU-MCI compared with the LOEU-CN group. Finally, parietal and occipital sources of alpha (8-12 Hz) rhythms were less active in the LOEU-MCI than in the NE-MCI and CN groups, while the opposite was true for frontal and temporal cortical delta sources. Discussion: MCI status was relatively frequent in LOEU patients, involved multiple cognitive domains, and might have been driven by amyloidosis according to CSF biomarkers. LOEU-MCI status was associated with abnormalities in cortical sources of EEG rhythms related to quiet vigilance. Future longitudinal studies should cross-validate our findings and test the predictive value of CSF and EEG variables., (Copyright © 2020 Nardi Cesarini, Babiloni, Salvadori, Farotti, Del Percio, Pascarelli, Noce, Lizio, Da Re, Isella, Tremolizzo, Romoli, DiFrancesco, Parnetti and Costa.)
- Published
- 2020
- Full Text
- View/download PDF
37. Appointment reminders to increase uptake of HIV retesting by at-risk individuals: a randomized controlled study in Thailand.
- Author
-
Salvadori N, Adam P, Mary JY, Decker L, Sabin L, Chevret S, Arunothong S, Khamduang W, Luangsook P, Suksa-Ardphasu V, Achalapong J, Rouzioux C, Sirirungsi W, Ngo-Giang-Huong N, and Jourdain G
- Subjects
- Adult, Cost-Benefit Analysis, Female, Humans, Male, Text Messaging economics, Thailand, Appointments and Schedules, HIV Infections drug therapy, Reminder Systems economics
- Abstract
Introduction: Frequent HIV testing of at-risk individuals is crucial to detect and treat infections early and prevent transmissions. We assessed the effect of reminders on HIV retesting uptake., Methods: The study was conducted within a programme involving four facilities providing free-of-charge HIV, syphilis and hepatitis B and C testing and counselling in northern Thailand. Individuals found HIV negative and identified at risk by counsellors were invited to participate in a three-arm, open-label, randomized, controlled trial comparing: (a) "No Appointment & No Reminder" (control arm); (b) "No Appointment but Reminder": short message service (SMS) sent 24 weeks after the enrolment visit to remind booking an appointment, and sent again one week later if no appointment was booked; and (c) "Appointment & Reminder": appointment scheduled during the enrolment visit and SMS sent one week before appointment to ask for confirmation; if no response: single call made within one business day. The primary endpoint was a HIV retest within seven months after the enrolment visit. The cost of each reminder strategy was calculated as the sum of the following costs in United States dollars (USD): time spent by participants, counsellors and hotline staff; phone calls made; and SMS sent. The target sample size was 217 participants per arm (651 overall)., Results: Between April and November 2017, 651 participants were randomized. The proportion presenting for HIV retesting within seven months was 11.2% (24/215) in the control arm, versus 19.3% (42/218) in "No Appointment but Reminder" (p = 0.023) and 36.7% (80/218) in "Appointment & Reminder" (p < 0.001). Differences in proportions compared to the control arm were respectively +8.1% (95% CI: +1.4% to +14.8%) and +25.5% (+17.9% to +33.2%). The incremental cost-effectiveness ratios of "No Appointment but Reminder" and "Appointment & Reminder" compared to the control arm were respectively USD 0.05 and USD 0.14 per participant for each 5% increase in HIV retesting uptake within seven months., Conclusions: Scheduling an appointment and sending a reminder one week before was a simple, easy-to-implement and affordable intervention that significantly increased HIV retesting uptake in these at-risk individuals. The personal phone call to clients probably contributed, and also improved service efficiency., (© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.)
- Published
- 2020
- Full Text
- View/download PDF
38. Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease.
- Author
-
Ramusino MC, Garibotto V, Bacchin R, Altomare D, Dodich A, Assal F, Mendes A, Costa A, Tinazzi M, Morbelli SD, Bauckneht M, Picco A, Dottorini ME, Tranfaglia C, Farotti L, Salvadori N, Moretti D, Savelli G, Tarallo A, Nobili F, Parapini M, Cavaliere C, Salvatore E, Salvatore M, Boccardi M, and Frisoni GB
- Subjects
- Amyloid beta-Peptides, Biomarkers, Humans, Peptide Fragments, Positron-Emission Tomography, tau Proteins, Alzheimer Disease diagnostic imaging, Cognitive Dysfunction diagnostic imaging
- Abstract
Purpose: To compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm., Methods: Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker., Results: Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P < 0.001); PET induced a diagnostic confidence increase significantly higher than CSF on both rounds 2 and 3., Conclusions: Amyloid-PET should be prioritized over CSF biomarkers in the diagnostic workup of patients investigated for suspected AD, as it provides greater changes in diagnosis and diagnostic confidence., Trial Registration: EudraCT no.: 2014-005389-31.
- Published
- 2020
- Full Text
- View/download PDF
39. Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study.
- Author
-
Liguori C, Costa C, Franchini F, Izzi F, Spanetta M, Cesarini EN, Di Santo S, Manfredi N, Farotti L, Romoli M, Lanari A, Salvadori N, Parnetti L, Calabresi P, Mercuri NB, and Placidi F
- Subjects
- Age of Onset, Aged, Aged, 80 and over, Anticonvulsants therapeutic use, Epilepsy drug therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Valproic Acid therapeutic use, Cognition physiology, Epilepsy physiopathology
- Abstract
Introduction: Epilepsy has a growing frequency, particularly in the elderly. Several triggers may cause late-onset epilepsy; however, more than 20% of epilepsies, manifesting in the elderly, has an unknown etiology. Although cognition is frequently altered in patients affected by epilepsy, there is a paucity of studies specifically evaluating cognition in patients affected by late-onset epilepsy. The aim of the present study was to assess the cognitive profile of patients affected by late-onset epilepsy with an unknown etiology and followed for 12 months., Methods: Patients affected by diagnosed late-onset epilepsy with unknown etiology were included in this observation. All patients were evaluated at the time of diagnosis (baseline) and at follow-up (12 months later). We distributed patients in subgroups based on seizure type (focal seizures [FS], secondarily generalized seizures [SGS], primarily generalized seizures [GS]) and antiepileptic drug (AED) regimen (mono- vs. polytherapy). Cognition was evaluated through standardized neuropsychological testing., Results: Fifty-eight patients were included in this observation and distributed in three groups: 29 affected by FS, 14 affected by SGS, 15 affected by GS. Forty-five patients were in monotherapy, and 13 in polytherapy. The most frequent treatments were levetiracetam (n = 12), valproic acid (VPA) (n = 9), carbamazepine (n = 9), and oxcarbazepine (n = 7). We documented a significant decrease of Mini-Mental State Examination (MMSE) and memory scores at follow-up in the whole group. Verbal learning decreased exclusively in VPA users., Conclusion: Patients affected by late-onset epilepsy with unknown etiology showed a significant decline of cognition at follow-up, independently from number and efficacy of AEDs received. These results deserve verification in larger longitudinal cohorts., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
40. Recommended First-Line Antiretroviral Therapy Regimens and Risk of Diabetes Mellitus in HIV-Infected Adults in Resource-Limited Settings.
- Author
-
Paengsai N, Jourdain G, Salvadori N, Tantraworasin A, Mary JY, Cressey TR, Chaiwarith R, Bowonwatanuwong C, Bhakeecheep S, and Kosachunhanun N
- Abstract
Objective: The use of some antiretroviral drugs has been associated with a higher risk of diabetes mellitus (DM) in HIV-infected patients, but the risk associated with antiretroviral drug combinations remains unclear. We investigated the association between first-line antiretroviral therapy (ART) regimens, recommended by the World Health Organization (WHO) in 2016, and the risk of DM in adults., Method: We selected all HIV-infected adults within the Thai National AIDS Program who started a first-line ART regimen consisting the following between October 2006 and September 2013: zidovudine+lamivudine+nevirapine; tenofovir disoproxil fumarate (TDF)+lamivudine+nevirapine; zidovudine+lamivudine+efavirenz; TDF+lamivudine/emtricitabine+efavirenz; zidovudine+lamivudine+ritonavir-boosted lopinavir (LPV/r); or TDF+lamivudine+LPV/r. Diagnosis of DM was defined as having at least 2 of the following characteristics: fasting plasma glucose ≥126 mg/dl, 2010 WHO ICD-10 codes E11-E14, or prescription of antidiabetic drugs. To identify ART regimens associated with DM, we used competing risks regression models that considered mortality without DM as a competing event and adjusted for sex, age, pancreas disease, and stratified by groups defined by a score summarizing the propensity to receive a specific first-line ART regimen., Results: Data from 35 710 adults (49.1% male; median age, 35.0 years; median follow-up, 2.0 years) were included. In the multivariable analysis with zidovudine+lamivudine+nevirapine as the reference group, a higher risk of DM was observed with TDF+lamivudine/emtricitabine+efavirenz (adjusted sub-distribution hazard ratio [aSHR], 1.6; 95% confidence interval [CI], 1.3-1.9), zidovudine+lamivudine+efavirenz (aSHR, 2.0; 95% CI, 1.7-2.3), and TDF+lamivudine+LPV/r (aSHR, 2.7; 95% CI, 1.9-3.9)., Conclusions: Several of the WHO recommended ART regimens, particularly tenofovir + lamivudine +LPV/r and regimens containing efavirenz, may be associated with an increased risk of DM., (© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2019
- Full Text
- View/download PDF
41. Incidence and risk factors of loss to follow-up among HIV-infected children in an antiretroviral treatment program.
- Author
-
Kawilapat S, Salvadori N, Ngo-Giang-Huong N, Decker L, Kanjanavanit S, Puangsombat A, Preedisripipat K, Lertpienthum N, Akarathum N, Mekmullica J, Srirompotong U, Lallemant M, Le Coeur S, Traisathit P, Leroi C, and Jourdain G
- Subjects
- Adolescent, Body Height, Body Weight, Child, Child, Preschool, Cohort Studies, Female, Follow-Up Studies, HIV Infections epidemiology, HIV Infections pathology, Humans, Incidence, Infant, Lost to Follow-Up, Male, Prospective Studies, Risk Factors, Thailand epidemiology, Time Factors, Anti-HIV Agents therapeutic use, HIV Infections drug therapy
- Abstract
Introduction: The success of antiretroviral treatment (ART) programs can be compromised by high rates of patient loss to follow-up (LTFU). We assessed the incidence and risk factors of LTFU in a large cohort of HIV-infected children receiving ART in Thailand., Methods: All children participating in a multicenter cohort (NCT00433030) between 1999 and 2014 were included. The date of LTFU was 9 months after the last contact date. ART interruption was defined as ART discontinuation for more than 7 days followed by resumption of treatment. Baseline and time-dependent risk factors associated with LTFU were identified using Fine and Gray competing risk regression models with death or referral to another hospital as competing events., Results: Of 873 children who were followed during a median of 8.6 years (interquartile range 4.5-10.6), 196 were LTFU, 73 died, and 195 referred. The cumulative incidence of LTFU was 2.9% at 1 year, 7.3% at 5 years and 22.2% at 10 years. Children aged 13 years and more had a 3-fold higher risk (95% confidence interval 2.06-4.78) of LTFU than those younger. Children who had interrupted ART within the previous year had a 2.5-fold higher risk (1.12-5.91) than those who had not. The risk of LTFU was lower in children stunted (height-for-age Z-scores <-2 SD) (0.42-0.96) or underweight (weight-for-age Z-scores <-2 SD) (0.24-0.97)., Conclusion: Adolescence, ART interruption and absence of growth deficit were associated with LTFU. These may be warnings that should draw clinicians' attention and possibly trigger specific interventions. Children with no significant growth retardation may also be at risk of LTFU., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
42. Long-Term Risk of Stroke After Transient Global Amnesia in Two Prospective Cohorts.
- Author
-
Romoli M, Tuna MA, McGurgan I, Li L, Giannandrea D, Eusebi P, Tordo Caprioli F, Lotti A, Salvadori N, Sarchielli P, Gili A, Mosconi MG, Pellizzaro Venti M, Stracci F, Ricci S, Paciaroni M, Parnetti L, Calabresi P, and Rothwell PM
- Subjects
- Adult, Aged, Case-Control Studies, Cohort Studies, Female, Humans, Ischemic Attack, Transient complications, Male, Middle Aged, Prospective Studies, Registries, Risk Factors, Stroke complications, Amnesia, Transient Global complications, Amnesia, Transient Global epidemiology, Ischemic Attack, Transient epidemiology, Stroke epidemiology
- Abstract
Background and Purpose- Transient global amnesia (TGA) is known as a benign syndrome, but recent data from neuroradiological studies support an ischemic cause in some cases, which might suggest an increased susceptibility to cerebrovascular events. We determined the long-term risk of stroke after a first TGA in 2 independent prospective cohorts. Methods- In 2 independent prospective cohorts of patients with TGA (OXVASC [Oxford Vascular Study], population-based; NU (Northern Umbria) cohort, TGA registry), cardiovascular risk factors and long-term outcomes, including stroke and major cardiovascular events, were identified on follow-up. Cardiovascular risk factors were treated according to primary prevention guidelines. In OXVASC, the age-/sex-adjusted risk of stroke during follow-up was compared with that expected from the rate in the underlying study population. Results- Among 525 patients with TGA (425 NU and 100 OXVASC), mean (SD) age was 65.1 (9.5) years and 42.5% male. Hypertension (58.1%), dyslipidemia (40.4%), and smoking (36.4%) were the most frequent cardiovascular risk factors. The risk of stroke was similar in the 2 cohorts, with a pooled annual risk of 0.6% (95% CI, 0.4-0.9) and a 5-year cumulative risk of 2.7% (1.1-4.3). Moreover, the stroke risk in OXVASC cases was no greater than that expected in the underlying study population (adjusted relative risk=0.73; 0.12-4.54; P=0.74). Conclusions- TGA does not carry an increased risk of stroke, at least when cardiovascular risk factors are treated according to primary prevention guidelines.
- Published
- 2019
- Full Text
- View/download PDF
43. Feasibility of using dried blood spots for HIV viral load testing among HIV-infected individuals in Thailand using QIAGEN QIAsymphony-artus HIV-1 platform.
- Author
-
Thepbundit V, Ngo-Giang-Huong N, Salvadori N, Laolue A, Kunyanone N, Sata-Un J, Jourdain G, Sirirungsi W, and Khamduang W
- Subjects
- Biomarkers, CD4 Lymphocyte Count, Female, Humans, Male, RNA, Viral, Sensitivity and Specificity, Thailand, Viral Load standards, Dried Blood Spot Testing methods, Dried Blood Spot Testing standards, HIV Infections diagnosis, HIV Infections virology, HIV-1 genetics, Reagent Kits, Diagnostic, Viral Load methods
- Abstract
In settings where plasma preparation and sample centralization are not feasible or inconvenient, dried blood spots (DBS) could be used as an alternative specimen to plasma to assess antiretroviral treatment response among HIV-infected individuals. This study was aimed to (1) validate the recent QIAsymphony-artus assay for DBS HIV viral load (VL) and (2) assess the feasibility of measuring HIV VL on DBS using this assay in Thailand. Ethylenediaminetetraacetic acid-blood samples from 99 HIV-infected individuals were used to prepare paired DBS and plasma. Also, DBS samples were shipped to three distant hospitals in the northern region. After short-term storage, DBS were returned by regular post to the AMS laboratory and were re-tested for HIV VL using the same platform. HIV VL results were compared using Pearson's correlation and Bland-Altman analysis. DBS HIV VL fairly correlated to plasma HIV VL (R = 0.62) with a mean difference of 0.02 log
10 IU/mL (SD = 1.06). A high correlation (R = 0.79) was observed between HIV VL in DBS before and after shipping (mean difference = 0.14 log10 IU/mL, SD = 0.74), indicating good stability of HIV RNA in DBS. DBS can be used as an alternative specimen for HIV VL monitoring in Thailand. However, measurement of HIV VL with the QIAGEN QIAsymphony-artus assay should be improved, especially the DBS pre-extraction process., (© 2019 Wiley Periodicals, Inc.)- Published
- 2019
- Full Text
- View/download PDF
44. Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.
- Author
-
Gaetani L, Salvadori N, Lisetti V, Eusebi P, Mancini A, Gentili L, Borrelli A, Portaccio E, Sarchielli P, Blennow K, Zetterberg H, Parnetti L, Calabresi P, and Di Filippo M
- Subjects
- Adult, Aged, Biomarkers cerebrospinal fluid, Cognitive Dysfunction psychology, Female, Humans, Male, Middle Aged, Multiple Sclerosis psychology, Neuropsychological Tests, Retrospective Studies, Cognitive Dysfunction cerebrospinal fluid, Cognitive Dysfunction diagnosis, Multiple Sclerosis cerebrospinal fluid, Multiple Sclerosis diagnosis, Neurofilament Proteins cerebrospinal fluid
- Abstract
Background: Cognitive impairment (CI) is a disabling symptom of multiple sclerosis (MS). Axonal damage disrupts neural circuits and may play a role in determining CI, but its detection and monitoring are not routinely performed. Cerebrospinal fluid (CSF) neurofilament light chain (NfL) is a promising marker of axonal damage in MS., Objective: To retrospectively examine the relationship between CSF NfL and CI in MS patients., Methods: CSF NfL concentration was measured in 28 consecutive newly diagnosed MS patients who underwent a neuropsychological evaluation with the Brief Repeatable Battery of Neuropsychological tests (BRBN)., Results: CSF NfL was higher in patients with overall CI (947.8 ± 400.7 vs 518.4 ± 424.7 pg/mL, p < 0.01), and with impairment in information processing speed (IPS) (820.8 ± 413.6 vs 513.6 ± 461.4 pg/mL, p < 0.05) and verbal fluency (1292 ± 511 vs 582.8 ± 395.4 pg/mL, p < 0.05), and it positively correlated with the number of impaired BRBN tests (r = 0.48, p = 0.01) and cognitive domains (r = 0.47, p = 0.01). Multivariate analyses taking into account potential confounders confirmed these findings., Conclusion: CSF NfL is higher in MS patients with CI and impaired IPS and verbal fluency. Large myelinated axons injury, causing neural disconnection, may be an important determinant of CI in MS and can be reliably measured through CSF NfL.
- Published
- 2019
- Full Text
- View/download PDF
45. Biomarker-Based Signature of Alzheimer's Disease in Pre-MCI Individuals.
- Author
-
Chipi E, Salvadori N, Farotti L, and Parnetti L
- Abstract
Alzheimer's disease (AD) pathology begins decades before the onset of clinical symptoms. It is recognized as a clinicobiological entity, being detectable in vivo independently of the clinical stage by means of pathophysiological biomarkers. Accordingly, neuropathological studies that were carried out on healthy elderly subjects, with or without subjective experience of cognitive decline, reported evidence of AD pathology in a high proportion of cases. At present, mild cognitive impairment (MCI) represents the only clinically diagnosed pre-dementia stage. Several attempts have been carried out to detect AD as early as possible, when subtle cognitive alterations, still not fulfilling MCI criteria, appear. Importantly, pre-MCI individuals showing the positivity of pathophysiological AD biomarkers show a risk of progression similar to MCI patients. In view of successful treatment with disease modifying agents, in a clinical setting, a timely diagnosis is mandatory. In clinical routine, biomarkers assessment should be taken into consideration whenever a subject with subtle cognitive deficits (pre-MCI), who is aware of his/her decline, requests to know the cause of such disturbances. In this review, we report the available neuropsychological and biomarkers data that characterize the pre-MCI patients, thus proposing pre-MCI as the first clinical manifestation of AD.
- Published
- 2019
- Full Text
- View/download PDF
46. The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease.
- Author
-
Biscetti L, Salvadori N, Farotti L, Cataldi S, Eusebi P, Paciotti S, and Parnetti L
- Subjects
- Aged, Aged, 80 and over, Biomarkers cerebrospinal fluid, Cohort Studies, Female, Humans, Male, Middle Aged, Alzheimer Disease cerebrospinal fluid, Alzheimer Disease diagnosis, Amyloid beta-Peptides cerebrospinal fluid, Peptide Fragments cerebrospinal fluid
- Abstract
The cerebrospinal fluid (CSF) signature of Alzheimer's disease (AD) includes abnormal levels of amyloid-β 1-42 (Aβ42), total tau (t-Tau) and phosphorylated tau (p-Tau). Several studies have reported that the CSF Aβ42/Aβ40 ratio could outperform CSF Aβ42 as a more accurate marker of brain amyloidosis, since it normalizes the CSF Aβ42 levels according to the total production of Aβ in the brain. In the present study, we wanted to assess the diagnostic utility of adding the Aβ42/Aβ40 ratio within the core AD CSF biomarkers for the classification of patients, according to NIA-AA criteria and Erlangen score. We consecutively recruited 168 patients (62 with AD and 106 with other neurological diseases) who referred to our Memory Clinic for diagnostic work- up from 2003 to 2016. The use of CSF Aβ42/Aβ40 ratio increased the percentage of correctly diagnosed AD patients from 72.0% to 82.8%. The high gain in sensitivity (from 75.8% to 85.5%) was obtained in face of loss of specificity (from 95.3% to 82.5%). Our study showed that the use of CSF Aβ42/Aβ40 could significantly improve the routine diagnostic work up of AD., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
47. Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.
- Author
-
Salvadori N, Fan B, Teeyasoontranon W, Ngo-Giang-Huong N, Phanomcheong S, Luvira A, Puangsombat A, Suwannarat A, Srirompotong U, Putiyanun C, Cressey TR, Decker L, Khamduang W, Harrison L, Tierney C, Shepherd JA, Kourtis AP, Bulterys M, Siberry GK, and Jourdain G
- Subjects
- Adult, Double-Blind Method, Female, Gestational Age, Hepatitis B virus, Humans, Infant, Male, Postpartum Period, Pregnancy, Pregnancy Complications, Infectious prevention & control, Pregnancy Complications, Infectious virology, Viral Load drug effects, Young Adult, Antiviral Agents therapeutic use, Bone Density drug effects, Hepatitis B drug therapy, Infectious Disease Transmission, Vertical prevention & control, Tenofovir therapeutic use
- Abstract
In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
48. Perinatal hepatitis B virus transmission in Lao PDR: A prospective cohort study.
- Author
-
Latthaphasavang V, Vanhems P, Ngo-Giang-Huong N, Sibounlang P, Paboriboune P, Malato L, Keoluangkhot V, Thammasack S, Salvadori N, Khamduang W, Steenkeste N, Trépo C, Dény P, and Jourdain G
- Subjects
- Adult, DNA, Viral blood, Female, Hepatitis B Surface Antigens blood, Hepatitis B e Antigens blood, Humans, Infant, Infant, Newborn, Male, Pregnancy, Prospective Studies, Vietnam epidemiology, Hepatitis B blood, Hepatitis B epidemiology, Hepatitis B prevention & control, Hepatitis B transmission, Hepatitis B Vaccines administration & dosage, Infectious Disease Transmission, Vertical, Pregnancy Complications, Infectious blood
- Abstract
Background: Mother-to-child transmission of hepatitis B virus (HBV) is the main cause of new infections worldwide. We aimed at assessing the percentage of infants successfully immunized in two major hospitals in Vientiane, Lao PDR where HB immune globulin (HBIg) is not available., Methods: We studied a prospective cohort of chronically HBV infected pregnant women and their infants until 6 months post-partum from January 2015 to March 2017. All infants received HB vaccine at birth and 6, 10 and 14 weeks thereafter, and HBV status was assessed at 6 months of age. HBV surface gene sequencing was performed in infected mother-infant pairs., Results: Of 153 mothers with HB surface antigen (HBsAg), 60 (39%) had detectable serum HBe antigen (HBeAg). HBeAg positive pregnant women were younger than those negative (median age 26 versus 28 years; p = 0.02) and had a significantly higher HBV viral load at delivery (median 8.0 versus 4.0 log10 IU/mL, p <0.001). Among the 120 infants assessed at 6 months of age, 5 (4%) were positive for HBsAg and had detectable HBV viral load by polymerase chain reaction. All were born to mothers with HBeAg and viral load >8.5 log10 IU/mL. However, only four (3.3%, 95% CI 0.5% to 7.0%) had a virus strain closely related to their mother's strain. HBV surface gene mutations were detected in 4 of the 5 infected infants. Anti-HBs antibody levels were below 10 IU/L in 10 (9%) uninfected infants at 6 months of age., Conclusions: Mother-to-child transmission occurred less frequently than expected without the use of HBIg. Adding HBIg and/or maternal antiviral prophylaxis may have prevented some of these infections. The observation of unsatisfactory levels of anti-HBs antibodies in 9% of the uninfected infants at 6 months highlights the need for improvement of the universal immunization procedures., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
49. Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis.
- Author
-
Parnetti L, Chipi E, Salvadori N, D'Andrea K, and Eusebi P
- Subjects
- Alzheimer Disease psychology, Cross-Sectional Studies, Humans, Longitudinal Studies, Prevalence, Risk Factors, Alzheimer Disease diagnosis, Alzheimer Disease epidemiology, Disease Progression, Prodromal Symptoms
- Abstract
Background: Alzheimer's disease (AD) pathology begins several years before the clinical onset. The long preclinical phase is composed of three stages according to the 2011National Institute on Aging and Alzheimer's Association (NIA-AA) criteria, followed by mild cognitive impairment (MCI), a featured clinical entity defined as "due to AD", or "prodromal AD", when pathophysiological biomarkers (i.e., cerebrospinal fluid or positron emission tomography with amyloid tracer) are positive. In the clinical setting, there is a clear need to detect the earliest symptoms not yet fulfilling MCI criteria, in order to proceed to biomarker assessment for diagnostic definition, thus offering treatment with disease-modifying drugs to patients as early as possible. According to the available evidence, we thus estimated the prevalence and risk of progression at each preclinical AD stage, with special interest in Stage 3., Methods: Cross-sectional and longitudinal studies published from April 2008 to May 2018 were obtained through MEDLINE-PubMed, screened, and systematically reviewed by four independent reviewers. Data from included studies were meta-analyzed using random-effects models. Heterogeneity was assessed by I
2 statistics., Results: Estimated overall prevalence of preclinical AD was 22% (95% CI = 18-26%). Rate of biomarker positivity overlapped in cognitively normal individuals and people with subjective cognitive decline. The risk of progression increases across preclinical AD stages, with individuals classified as NIA-AA Stage 3 showing the highest risk (73%, 95% CI = 40-92%) compared to those in Stage 2 (38%, 95% CI = 21-59%) and Stage 1 (20%, 95% CI = 10-34%)., Conclusion: Available data consistently show that risk of progression increases across the preclinical AD stages, where Stage 3 shows a risk of progression comparable to MCI due to AD. Accordingly, an effort should be made to also operationalize the diagnostic work-up in subjects with subtle cognitive deficits not yet fulfilling MCI criteria. The possibility to define, in the clinical routine, a patient as "pre-MCI due to AD" could offer these subjects the opportunity to use disease-modifying drugs at best.- Published
- 2019
- Full Text
- View/download PDF
50. Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.
- Author
-
Cressey TR, Harrison L, Achalapong J, Kanjanavikai P, Patamasingh Na Ayudhaya O, Liampongsabuddhi P, Siriwachirachai T, Putiyanun C, Suriyachai P, Tierney C, Salvadori N, Chinwong D, Decker L, Tawon Y, Murphy TV, Ngo-Giang-Huong N, Siberry GK, and Jourdain G
- Subjects
- Administration, Oral, Adult, Antiviral Agents blood, Antiviral Agents pharmacology, Area Under Curve, Female, Hepatitis B Surface Antigens blood, Hepatitis B virus growth & development, Hepatitis B, Chronic virology, Humans, Postpartum Period, Pregnancy, Tenofovir blood, Tenofovir pharmacology, Viral Load drug effects, Antiviral Agents pharmacokinetics, Hepatitis B virus drug effects, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic transmission, Infectious Disease Transmission, Vertical prevention & control, Tenofovir pharmacokinetics
- Abstract
We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC
0-24 ]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC0-24 was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed., (Copyright © 2018 American Society for Microbiology.)- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.